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ABSTRACT
OBSERVING THE MOLECULAR BASIS OF THIN FILAMENT ACTIVATION
WITH A THREE BEAD LASER TRAP ASSAY
FEBRUARY 2018
THOMAS J. LONGYEAR, B.S., UNIVERSITY OF ALABAMA HUNTSVILLE
M.S., UNIVERSITY OF MASSACHUSETTS
Ph.D., UNIVERSITY OF MASSACHUSETTS
Directed by: Professor Edward P. Debold
Muscle contracts after calcium (Ca++) is released into the muscle cell, resulting
from a cascade of events which result in myosin, the molecular motor of muscle, to
produce force and motion. Myosin cyclically binds to a regulated thin filament, using the
chemical energy of ATP to produce force and motion. Perturbations in muscle, such as a
build-up of metabolic by-products or point mutations in key contractile proteins, can
inhibit these functions in both skeletal and cardiac muscle either acutely or chronically.
Despite the many years we have studied skeletal and cardiac muscle, we still do not have
a clear picture of the effect of these perturbations at the molecular level. Indeed, we do
not even have a clear picture of how muscle is activated at the molecular level. Such an
understanding would provide a foundation for future work, and aid our understanding of
perturbations such as muscle fatigue or point mutations. Recent advances in biophysical
techniques have allowed us to directly observe both single myosin and small ensembles
of myosin interacting with an actin filament. We build off this previous work by
examining 1) a single myosin molecule interacting with a regulated actin thin filament,
and 2) small ensembles of myosin working together to pull on a regulated thin filament.
We set out to directly determine how Ca++ and myosin activate the thin filament and thus
vi

muscle. Our approach to directly observe these molecular phenomena across
physiological Ca++ levels as well as high ATP concentrations is novel. The first goal of
this work was to examine how 1) a single myosin interacts with a regulated thin filament
and 2) how a small ensemble of myosins work together to generate force and motion in a
Ca++ dependent manner as they interact with a regulated thin filament. The findings build
on previous work using similar techniques, but are rich in data and provide a more
physiological viewpoint. The second goal of this work was to examine a particular
mutation that leads to hypertrophic cardiomyopathy. The current evidence suggests that
this mutation alters both thin filament dynamics and myosin kinetics. This mutation was
thus chosen not only to add to our understanding of this particular mutation in hopes of
developing a therapeutic, but also to provide insight into the role of thin filament
activation and myosin dynamics in hopes of better understanding muscle contraction
overall. With our experiments, supplemented with a mathematical model, we have deconvolved the role of Ca++ and myosin in thin filament activation, and developed a model
of muscle activation from the single molecule up to the scale of a cell.
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CHAPTER 1
INTRODUCTION
For over 100 years, the machinery and mechanism for muscle contraction has
been studied. Despite this long history, there are many unresolved questions, particularly
on the molecular level. How a single myosin molecule interacts with a regulated actin
filament (also called a ‘regulated thin filament’) is unknown. Further, how a small
ensemble of myosins work together to bind to a regulated actin filament to produce force
and motion is not clear. Considering in vivo muscle is structured so that a small ensemble
of myosins interact with a regulated thin filament, experiments that can directly observe
these conditions would be extremely valuable. We know that during a muscle
contraction, calcium (Ca++) is released into the muscle cell, leading to partial activation of
the regulated thin filament. Myosin can then strongly bind to the thin filament, leading to
complete activation. However, the details of this thin filament activation are unclear. The
relative contribution of Ca++ and myosin to thin filament activation is of particular
interest if we are to better understand the molecular processes of muscle. The complete
understanding of thin filament activation is applicable to many conditions, including
submaximal Ca++, muscle fatigue, or point mutations.
Muscle fatigue is defined as a transient decrease in the generation of force and/or
velocity in response to exercise (32, 38). Muscle fatigue has fundamental implications for
exercise physiology, but is also a debilitating symptom of heart failure, which limits
physical activity and negatively impacts the patient’s prognosis (43, 99). Despite the
importance and history of muscle fatigue, the etiology of fatigue is not fully understood.
A major hurdle to our understanding is our inability to observe molecular phenomena that
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cause muscle fatigue. In fact, the inability to observe molecular phenomena has hindered
our understanding of the molecular machinery of muscle even under normal conditions,
let alone fatigue like conditions. Before further examining the etiology of fatigue, a better
understand how the molecular machinery of muscle works under normal conditions
would be of great benefit. A major goal of this dissertation was to provide insight into the
molecular details of muscle contraction, and lay a foundation for future work the examine
the molecular details of muscle fatigue.
Macroscale experiments that include human or animal participants, whole muscle,
and even single muscle fibers have been informative, but are unable to provide
information on the molecular details of muscle function, and thus muscle fatigue. Despite
a long history of study, only in the last 20 years have we been able to directly examine
muscle structure and function at the single molecule level (37). With new techniques now
in hand, such as the laser trap assay, a better understanding of muscle function on the
molecular level can be obtained. We can now examine the role of myosin and the
regulatory proteins during muscle activation.
What follows is a description of our current understanding of the molecular
machinery of muscle, including myosin and the regulated thin filament. In addition, we
will discuss how this machinery and its function leads to macroscopic observations, and
how these observations change with perturbations such as fatigue or mutations in key
contractile proteins. Finally, we will discuss experiments that can be performed that
would address our questions about myosin’s function and thin filament activation under
normal conditions, as well as under conditions with specific perturbations.
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At the molecular level, muscle contraction is driven by myosin, which is the
molecular motor in muscle. Myosin is an ATPase, converting the chemical energy of
ATP into mechanical work. Within a muscle fiber, myosin molecules are organized into a

Figure 1.1 Model of the crossbridge cycle. During skeletal muscle contraction, myosin strongly binds to actin,
releases Pi, and generates a powerstroke (step 1). Myosin then goes through an isomerization (with no
biochemical change, step 2) and then releases ADP (step 3). ATP then binds to myosin, causing actomyosin
dissociation (step 4). Myosin then hydrolyzes ATP (step 5) and the cycle repeats. It is possible that acidosis slows
each of these steps.

thick filaments and are able to bind to the thin filament, composed of actin. The myosin
molecules cyclically bind to the thin filament, producing force and motion with each
binding event. This cycle starts when myosin binds to actin and generates a
“powerstroke” of approximately 10 nm (figure 1.1, step 1) (25, 37, 119). Myosin then
releases one of the ATP hydrolysis products, inorganic phosphate (Pi), into the cytosol,
and this release is in close temporal proximity to this powerstroke (5, 20, 33). Some
hypothesize that myosin then goes through an isomerization (26, 106), where there is
some slight structural change without a biochemical change (step 2) (21, 26, 106).
Myosin then releases ADP into the cytosol (step 3) and an ATP molecule will then bind
to myosin, causing dissociation of myosin and actin (step 4). Myosin will hydrolyze the
ATP (step 5) and the cycle repeats; this cycle is known as the “crossbridge cycle”. Each
cycle generates an approximate 10 nm displacement. Thus, the faster myosin can move
3

through the cycle, the more displacement will be generated in a given time, and therefore
more velocity is generated. Because myosin is the molecular motor of muscle, the speed
at which the crossbridge cycle occurs is the direct cause of muscle contraction velocity.
In addition, the force muscle produces is the product of the number of myosin’s attached
to the regulated thin filament and how much force each myosin produces.
In order to fully understand the crossbridge cycle, we need to know how the
myosins interact with regulated actin, as is the case in vivo. Our understanding should
include not only rested conditions, but also conditions observed during fatigue in vivo.
These fatigue conditions can alter myosin’s function, resulting in changes in thin filament
activation. Previous work has shown that specific changes within the muscle that occur
during fatigue (13, 23, 64) lead to a reduction in force and velocity, most likely by
altering myosin’s crossbridge cycle. For example, reducing the pH from 7.0 to 6.2 led to
a decrease in force by 3-14%, velocity by 10-30%, and power by 34% (63, 67, 88).
However, which step(s) of the crossbridge cycle are affected by acidosis is unclear. ATP
hydrolysis, myosin’s strong binding to the thin filament, and/or ADP release may be
altered; however, this has not been directly observed (25, 82, 100, 105). In addition, there
is evidence that acidosis alters myosin’s force generating capacity (82). Previous work in
single muscle fibers has suggested that a decrease in pH from 7.0 to 6.2 leads to a
decrease in stiffness by approximately 25% (82). However, these data were collected
with single muscle fibers (which contain billions of myosin molecules) at below
physiological temperatures (10 or 15° C). Such experiments with billions of myosin
molecules don’t provide direct insight into the effects of acidosis on myosin’s function,
and temperature has been shown to have a significant impact on myosin’s on-rate as well
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as the effect of acidosis (95, 96, 137). Experiments with a single myosin molecule at
near-physiological temperatures (30° C) can be performed with a laser trap assay to
address this. This assay can be used to not only understand the molecular details of
muscle under normal conditions, but also under fatigue-like conditions. Experiments
exploring fatigue can be performed in future work once we have a better picture of how
myosin works under normal conditions.
Clearly, myosin plays a key role in muscle’s function, and specific perturbations
that alter muscle output are due to direct effects on myosin. Additional key players
include the regulatory proteins, troponin (Tn) and tropomyosin (Tm). The interaction
between myosin and actin is regulated by Ca++ binding to troponin. This Ca++ binding
will lead to a chain of events, involving structural and dynamic changes in troponin,
tropomyosin, myosin and actin, eventually leading to muscle contraction. Troponin
consists of three subunits: the Ca++ binding subunit, troponin C (TnC), the inhibitory
subunit, which is responsible for inhibiting contraction during muscle relaxation, troponin
I (TnI), and the tropomyosin binding subunit, troponin T (TnT). Ca++ binding to TnC
leads to slight structural changes the TnC structure, where a hydrophobic patch is
exposed on the N-terminus. The C-terminus of TnI, which plays the crucial role of
binding to actin and keeping the regulatory proteins in place during relaxation and
preventing actomyosin binding, will relieve itself of this duty by releasing actin and
binding to the exposed hydrophobic patch. With only minor forces keeping tropomyosin
on actin, tropomyosin is now free to slide over the actin surface, which reveals myosin
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binding sites on actin (see figure 1.2).

Figure 1.2. Cartoon of TnI at low and high calcium. a) With no calcium bound to troponin C, troponin I stays
bound to actin, keeping tropomyosin in the blocked state. b) Upon calcium binding, troponin I detaches from
actin and binds to troponin C, allowing tropomyosin to move freely about the actin surface.

The function of regulatory proteins is crucial; minor changes in Ca++
concentrations can lead to large changes in troponin and tropomyosin’s position on actin,
and thus can lead to large changes in muscle force. Therefore, perturbations that alter
Ca++ binding to troponin or that alter troponin’s function can have significant
implications. For example, mutations in troponin can lead to cardiomyopathies by
presumably altering these Ca++-dependent motions. In addition, during muscle fatigue,
Ca++ levels decrease (71) and positively charged hydrogen ions may compete with Ca++
for binding to troponin (88, 93). Both mechanisms can lead to a drastic reduction in
muscle output. The precise molecular mechanisms are unknown.
Prior to Ca++ release, tropomyosin is in the “blocked” state, where tropomyosin
physically blocks actomyosin binding. Upon Ca++ binding to troponin, tropomyosin is
moved into the “closed” state, where tropomyosin’s position fluctuates across actin’s
surface and binding sites are transiently available to myosin. Once in the closed state,
tropomyosin is pushed into the “open” state upon myosin binding. This premise, known
as the three state model, is strongly supported by biochemical experiments (72, 81, 118),
6

in vitro experiments (29, 62), protein structures (19, 98, 108, 122, 125), and mathematical
models (126). Thus, both Ca++ binding to troponin and myosin binding to actin are
critical to thin filament activation, where thin filament activation is a measure of how
available the myosin binding sites on actin are. As stated earlier, perturbations such as
troponin mutations or fatigue-like conditions can alter muscle output. In the three-state
model, acidosis may block Ca++ binding to troponin, potentially keeping tropomyosin in
the blocked state. This would result in less actomyosin binding and thus less muscle
output. This reduced binding not only affects each myosin, but can also affect
neighboring myosin due to the cooperative nature of myosin binding.
A key component of thin
200
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pCa
Figure 1.3. Typical force-pCa relationship. A muscle
fiber’s force generating capacity is dependent on the Ca++
concentration. The curve is sigmoidal, and the curve is
steep, suggesting high cooperativity.

and pCa-velocity relationships, an example of which is shown in figure 1.3. In this figure,
the x-axis is pCa, which represents the negative log of Ca++ (pCa 4 is high Ca++, pCa 7 is
relatively low Ca++). Force output is very low at low Ca++ levels, but as Ca++ increases, a
drastic increase in force occurs. As more Ca++ is present, the regulatory proteins can more
readily move out of the blocked state, and myosin can bind. Clearly, both Ca++ and
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myosin play a crucial role in thin filament activation, but is one more important than the
other? The precise role of each of these players in thin filament activation and
cooperativity are not completely understood. Understanding these roles is significant to
both skeletal and cardiac muscle because during muscle activation, the physiological
Ca++ concentration usually lies within the steep portion of the pCa-force relationship.
Small changes in Ca++ can lead to large changes in myosin binding and subsequent force
production. Further, how activation and cooperativity are altered by acidosis and other
metabolites produced during fatigue is unclear, though evidence exists that acidosis
affects these parameters (22, 24, 88, 93, 133, 135). Therefore, understanding the roles of
myosin and Ca++ under normal conditions is imperative so that we can better understand
the molecular details of fatigue in subsequent experiments. A key goal of this
dissertation was to determine the role of myosin and Ca++ in thin filament
activation. This was achieved with the state-or-the-art laser trap assay that allows
direct observation of single myosin and myosin ensembles generating force. By
directly observing the binding of a single myosin or an ensemble of myosin to a
regulated thin filament while controlling the level of Ca++, we de-convolved the role
of both myosin and Ca++ in activation.
With a better understanding of how myosin and the regulatory proteins lead to
thin filament activation, we will be able to understand how specific perturbations affect
thin filament activation, as well as cooperativity and the resulting pCa-force relationship.
For example, mutant troponins can lead to changes in these measures. The mutations that
lead to muscle dysfunction are typically found in key regions of troponin. One key region
is the Ca++ binding pocket. Obviously, a mutation here could alter Ca++ binding and
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subsequent thin filament activation. Another key region is the inhibitory region, which
binds to actin and prevents tropomyosin from moving and exposing actomyosin binding
sites. A mutation in this region could allow tropomyosin to expose actomyosin binding
sites in the absence of Ca++. One example of this is a mutation called R146G. This
mutation is associated with hypertrophic cardiomyopathy and seems to allow actomyosin
binding in the absence of Ca++ (34, 70, 114, 129). Unfortunately, the precise mechanism
R146G’s action is unknown. More precise techniques are required to understand its effect
on thin filament activation and potentially help the patients with this mutation. A second
key goal of this dissertation was to examine how R146G has its effects on myosin
kinetics and regulated thin filament activation.
To obtain a better understanding of thin filament activation, experiments on the

Figure 1.4. Cartoon of the 3-bead assay. Myosin is randomly oriented on the microscope slide surface,
occasionally located on a pedestal bead. A bead-filament-bead assembly, trapped by laser light, is put in close
vicinity to the pedestal so single molecule interactions can be observed and measured. Figure courtesy of Mike
Woodward.

molecular level that can examine a single myosin’s ability to interact with the thin
filament are crucial. Further, experiments that mimic physiological conditions by
examining how a small ensemble of myosin work together to activate the thin filament
9

could bridge the gap between our current understanding of single myosin molecule
kinetics and single muscle fiber experiments. This can be achieved with the 3-bead laser
trap assay, where two beads, which are trapped by laser light, hold a single actin filament
taught, while a single myosin sitting on a pedestal bead binds to the actin filament (figure
1.4). This technique, with millisecond time and nanometer spatial resolution, allows us to
directly observe a single molecule interaction, giving us displacement, duration of
attachment, and binding frequency of individual actomyosin interactions. This technique
can also be used to examine how multiple myosins pull on a single actin filament
cooperatively to generate force.
In addition to collecting novel information on thin filament activation, a key
outcome from future work is to be able to use our knowledge of the molecular details to
understand how specific perturbations lead to dysfunction. In addition to setting the
foundation for examining fatigue, the knowledge gained in this work can set the
foundation for examining mutations that cause disease. Our understanding of the
molecular details of normal, wildtype proteins can help us construct models for
mutations, especially those that cause cardiomyopathies.
The expectation for this dissertation was to create a better understanding of
muscle on the molecular level and begin applying that knowledge to specific
perturbations. One perturbation that we have gained interest in is the R146G mutation in
TnI. This mutation was chosen because it is known to cause cardiomyopathy (60, 65),
because of its crucial location in TnI (36, 113, 115), and because the evidence is
inconclusive. Though this mutation has been studied previously, there is still little
consensus on its effect. For example, some have shown that the R146G negatively affects
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force, while others have seen no effect (70, 114, 129, 132). More puzzling is the effect
this mutation has on the Ca++ dependent production of force and velocity: previous data
has shown that force and velocity are reduced at high Ca++ compared to wildtype Tn, but
force and velocity are increased at low Ca++ (12, 60, 69, 70, 114, 129, 132). The
molecular mechanisms that lead to these odd phenomena are not well understood.
Experiments that examine both thin filament activation as well as myosin kinetics in the
presence of this mutation are necessary to gain a full mechanistic understanding of this
mutation. By manipulating conditions in an in vitro environment, we can gain novel
insight into how this mutation causes dysfunction. Future work can then use our
understanding of the molecular details of muscle contraction to ameliorate the negative
effects of cardiomyopathies.
Overall, the goal of this dissertation was to use state-of-the-art single molecule
techniques to better understand regulated thin filament activation. In recent years, many
experiments have been performed with either single muscle fibers which contain billions
of myosin or with single myosin molecules interacting with an unregulated thin filament.
The current dissertation bridges the gap between these two methods by incorporating
regulated thin filaments with single, small ensemble, and large ensembles of myosin.
This work lays the foundation for future work examining perturbations that cause muscle
fatigue. Another key goal was to better understand how a cardiomyopathy mutation in
troponin leads to functional changes. These outcomes give us a better understanding of
the molecular details of muscle contraction and help us apply our knowledge to attenuate
the negative effects of cardiomyopathy mutations.
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Hypotheses
Hypothesis 1: Both Ca++ and myosin play crucial roles in thin filament activation.
A) During single molecule experiments in the 3-bead assay, myosin’s binding to
the regulated thin filament will be Ca++ dependent.
a. The frequency of binding will be reduced as Ca++ levels are reduced.
b. The displacement generated upon myosin binding will not be Ca++
dependent.
B) During experiments with small ensembles of myosin in the 3-bead assay, the
force generated will be Ca++ dependent and will show elements of
cooperativity.
a. Many events will be recorded with various forces, and the distributions
will shift as Ca++ is decreased where force and event frequency will
decrease.
b. The distributions will show cooperativity by containing many events
with high force. This cooperative action will be observed by direct
observation of moderate forces even at low to moderate calcium (pCa
6-7).
i. This suggests that once one myosin binds, many others bind as
well, leading to a distribution of forces with more high forces
than low forces.
C) During experiments with large ensembles of myosin in an in vitro motility
assay, the velocity generated will be dependent on both ATP, which directly
influences the number of myosin bound, and Ca++ concentrations.
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a. Under conditions of low ATP and low Ca++, velocity will be observed,
suggesting that myosin in rigor can activate the thin filament in the
absence of Ca++.
b. This suggests that both myosin and Ca++ play a role in thin filament
activation. Under low ATP and low Ca++, activation is driven by
myosins that are strongly bound in a rigor state, while high ATP and
high Ca++ leads to contributions from both strongly bound myosin and
Ca++.
Hypothesis 2: The R146G mutation in troponin I disrupts the normal pCa-velocity
relationship by altering multiple steps of the crossbridge cycle.
A) During pCa-velocity experiments, the R146G mutation will lead to enhanced
velocity under low Ca++ conditions but reduced velocity under high Ca++
conditions.
a. This will lead to a reduced Hill coefficient, which suggests a reduction in
cooperativity.
b. The mutation will also cause an increase in the Ca++ sensitivity, as
determined by the pCa50.
B) During duty cycle experiments, the R146G mutation will cause an increase in the
duty cycle.
a. This will suggest that the R146G affects myosin kinetics, either increasing
the rate of the strong binding step or slowing the rate of ADP release. The
most likely steps altered are strong binding and ADP release.
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C) During ATP-velocity experiments, the R146 mutation will slow velocity at any
given ATP level, suggesting that ADP release is slowed in the presence of the
R146G mutation.

14

CHAPTER 2
LITERATURE REVIEW
The Crossbridge Cycle
Myosin uses energy from ATP hydrolysis to cyclically bind to actin and produce
force and motion. This cyclical binding is commonly referred to as the crossbridge cycle.
When a muscle is in a resting state, most myosin are in a ‘cocked’ state, with the myosin
head ready to bind to actin and release its hydrolysis products, ADP and Pi. Upon muscle
activation, Ca++ binds to troponin and the regulatory proteins allow myosin to strongly
bind to actin. When this occurs, myosin releases Pi, generates force, and produces an
approximate 10 nm displacement of actin, all in a matter of a few milliseconds (37).
Myosin continues to produce force as long as it is strongly bound to actin, the duration of
which is referred to as “time-on” (ton). During this strongly bound state, there is evidence
that myosin isomerizes with ADP still bound (26, 106). Myosin then releases ADP and
binds an ATP molecule, which causes dissociation of myosin and actin. From here,
myosin can hydrolyze this ATP molecule, which re-cocks the myosin head, and the
crossbridge cycle can begin again.
The crossbridge cycle affects force and velocity
To discuss myosin’s function, we must discuss what limits myosin’s function and
its subsequent force and velocity production. The force generated by a muscle fiber is the
product of the number of myosin molecules in that fiber strongly bound to actin
multiplied by the force per myosin molecule (58, 59). Therefore, the longer myosin stays
attached to actin (i.e., ton) relative to the time off of actin (toff), the more myosin
molecules will be bound at any given time, increasing the force produced. Based on this,
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an increased rate in attachment and a decreased rate of detachment would lead to more
myosin bound and thus more force. Experiments performed in the laser trap assay have
shown that specific biochemical steps are force dependent, such as ADP release (121).
The more force a given myosin is producing, the longer myosin would take to release
ADP. This provides a mechanochemical explanation for prolonged attachment and high
force production. Velocity, on the other hand, is assumed to be limited by detachment
(59, 128), that is, velocity is equal to the displacement generated by myosin divided by
the time myosin spends strongly bound to actin (59). The faster myosin can detach, the
faster a muscle will contract. This model agrees well with data suggesting that ADP
release, an event that occurs with myosin bound to actin, is the biochemical step that
limits velocity (91). Simply, force is dependent on myosin being bound to the actin
filament, while velocity is dependent on the rate of detachment from the actin filament.
This juxtaposition is the basis for the inverse relationship of force and velocity. This
relationship was shown in seminal work by A.V. Hill (55) in whole muscle. Evidence
that myosin is responsible for this action was demonstrated with the laser trap assay,
where a small ensemble of myosin was able to reproduce the force-velocity relationship
(27).
Effect of metabolites on the crossbridge cycle
Changes to the concentration of specific metabolites can affect the kinetics of the
crossbridge cycle. Some of these metabolites have been suspects for muscle fatigue. This
includes ATP, inorganic phosphate (Pi), and acidosis.
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ATP
A reduction in ATP was once considered a culprit of fatigue. As ATP
concentrations are reduced, the rigor lifetime of a myosin crossbridge increases, which
would slow velocity. Current estimates put ATP levels around 5 mM in fresh muscle, and
as low as 1 mM in severely fatigued muscle (2). However, 1 mM is more than sufficient.
The concentration of ATP that leads to half-maximal binding of myosin, also known as
the Km, is approximately 5 uM. Therefore, a decrease to 1 mM would still allow
sufficient ATP-myosin binding, and would not have a significant effect on myosin’s
function.
Inorganic Phosphate (Pi)
Another major culprit of muscle fatigue is inorganic phosphate (Pi). Even small
amounts of Pi (5 mM) can negatively impact force (18, 20, 28), though some have
postulated that concentrations can reach as high as 30 mM during fatigue (13, 23, 134). Pi
release and force generation have been examined extensively, as Pi release is closely
associated with force generation and are hard to tease apart. One current hypothesis is
that Pi rebinds to actomyosin, inducing dissociation between actin and myosin and thus
limiting force production. This hypothesis was validated with single molecule
experiments in the laser trap assay recently (28).
Acidosis
Finally, acidosis is likely to be the most studied culprit for muscle fatigue.
Acidosis has been proposed to affect more than one step of the crossbridge cycle.
Surprisingly, there is relatively little evidence showing which kinetic step is altered.
Recent work has shown force to decline 10-18% and velocity to decline by up to 70%
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(63, 67, 88). For this to occur, specific steps of the crossbridge cycle must be slowed.
Based on the steps that limit force and velocity, three steps are likely slowed: 1) the
strong binding, force-generating step, 2) ADP release, and 3) ATP hydrolysis.
The first potential step acidosis may alter is myosin’s strong binding to actin.
Insightful release and re-stretch experiments performed in single muscle fibers suggested
that strong binding was slowed (83). In fact, later work suggested that the acidosisinduced changes observed in both force and velocity could be explained by this one
step’s rate (105). Additional work comparing the change in force and ATPase as a
function of pH also suggested that the rate of attachment is slowed as pH is reduced
(100). One technique that could address the rate of strong binding is the single molecule
laser trap assay. In this assay, individual binding events between myosin and the thin
filament can be directly observed. The rate of strong binding can be determined by
recording the number of events over time and determining the binding frequency. This
binding frequency can be measured in the presence or absence of acidosis and the effect
of acidosis on strong binding can be observed and quantified.
The second kinetic step that could be altered by acidosis is ADP release. There is
strong evidence that ADP release is slowed by acidosis, where reducing the pH from 7.4
to 6.4 increased the lifetime of a single actomyosin bond 3-fold (25). This was directly
observed in the laser trap assay, where the displacement and binding lifetime of a single
myosin molecule interacting with a single filament can be directly observed.
Finally, the third step likely to be altered by acidosis is ATP hydrolysis. The
single molecule experiments performed by Debold et al. (25) suggested that ATP
hydrolysis was slowed by acidosis. This was suggested based on the average
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displacement observed for each powerstroke under various conditions: at low ATP (1
µM), the average displacement was only 2 nm, but this was increased to 6 nm at 10 µM
ATP and returned to a normal 10 nm at 1 mM ATP. The authors argue that acidosis does
not alter the size of the powerstroke, because the powerstroke size returned to 10 nm at
high ATP. Rather, they suggest that ATP hydrolysis is slowed. The logic is as follows: up
ATP binding, myosin and actin dissociate (step 4, figure 1). However, if ATP hydrolysis
is slowed, myosin may release ATP and bind to actin, forming a strong bond but
producing no powerstroke. Thus, in the laser trap assay, an actomyosin binding event
would be detected but no displacement generated. If such events happened frequently, the
average displacement of all events would be skewed toward values much less than 10
nm, as observed. As ATP concentrations increase to 10 µM and 1 mM, myosin could
release ATP, but a new ATP could quickly take its place, and the crossbridge cycle
would move forward.
Recent work from our group (26, 76) has teased apart which crossbridge steps
acidosis alters. In the presence of acidosis, we observed a slowing of thin filament
velocity, which was augmented in the presence of Pi. We postulated that acidosis slows a
step during ton (possibly the AM.ADP state), and Pi rebinds to this step, causing
dissociation of actomyosin. This agrees well with a detachment-limited model of
velocity, where a faster dissociation (caused by Pi) would attenuate acidosis’ effect on
velocity. We further probed this by measuring velocity in the presence of ADP and Pi.
Interestingly, Pi could not attenuate the negative effects of ADP on velocity. We
concluded that there are two myosin-ADP states: AM’ADP and AM.ADP, the transition
of which is slowed by acidosis. Further, we concluded that Pi can rebind to the AM’ADP
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state, causing
dissociation and thus
limiting acidosis’
effects on velocity.
However, the addition
of ADP leads to an
increase in the
AM.ADP state, a state

Figure 2.1. Action of Pi rebinding to actomyosin. Pi can rebind to the AM'ADP
state, but not the AM.ADP state. Acidosis slows the AM’ADP to AM.ADP
transition. Pi can rebind to this state, causing dissociation of actomyosin and
thus attenuate acidosis’ effect on velocity. The addition of ADP increases the
AM.ADP state, a state to which Pi cannot rebind and cannot attenuate velocity.

that Pi cannot rebind to and thus cannot affect (see Figure 3.1). Further experiments with
2-deoxy-ATP (dATP), an ATP analog, showed that dATP can mitigate the effects of
acidosis in the presence or absence of Pi. We concluded that acidosis must slow the
weak-to-strong transition, while dATP attenuates this effect. Indeed, previous work has
suggested that dATP increases the weak-to-strong transition rate (101, 102).
Though we have made strides toward understanding the effects of acidosis, a
clearer picture can be obtained by dissecting each step of the crossbridge cycle. Indeed,
single molecule experiments are necessary to directly observe and measure the steps of
the crossbridge cycle. One example of the power of single molecule experiments is the
results obtained from Debold et al. (25) which directly measured that the rate of ADP
release is reduced in the presence of acidosis, in disagreement with inferences made from
single fiber data. Additional experiments that could be done to make the conditions more
physiological would be to measure the rate of certain kinetic steps in the presence of
regulatory proteins. Finally, if ATP hydrolysis is slowed in the presence of acidosis is
hard to determine. Debold et al. suggests this is possible, and solution kinetics suggest
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that myosin can release ATP and rebind to actin (107). If any step in the crossbridge is
slowed by acidosis, myosin’s overall rate of ATP hydrolysis, measured as the ATP
consumed per second, should decline as the pH is reduced. Interestingly, ATPase
experiments have been inconclusive, as some actually suggest an increase in ATPase rate
as pH decreases (100), some show no change (7, 8) while others suggest a 10% decrease
(109). Clearly, experiments that can tease apart the individual steps of the crossbridge are
necessary to characterize acidosis’ full effects.
Acidosis may not only affect myosin’s kinetic steps, but also the force each
myosin can produce. This possibility has been hypothesized previously based on single
muscle fiber experiments (82, 100, 105). Some of the evidence is based on assumptions
of myosin kinetics based on single fiber measurements (100, 105), while Metzger and
Moss (82) provided convincing evidence of a decrease in force per crossbridge by
observing a decrease in fiber stiffness relative to the force production of the fiber (82). In
these experiments, the crossbridges were held in rigor by excluding ATP from the fiber
bathing solution, and then the fiber was exposed to fast, sinusoidal changes in length so
that both force and stiffness could be measured. From these experiments, one could
conclude that force per crossbridge is decreased in the presence of acidosis. One
confounding factor of these observations is that the changes in stiffness observed with
acidosis are assumed to have occurred due to alterations in myosin’s mechanical
characteristics, an assumption that ignores the fact that other proteins within a muscle
fiber play crucial roles in fiber structure and stiffness. For example, titin is a large protein
in muscle fibers that passively produces stiffness when a fiber is stretched and this
stiffness is subject to the concentration of particular molecules, such as Ca++ (73). Titin
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and other molecules are also sensitive to acidosis and could also therefore lead to the
observed change in stiffness. To tease apart the direct effect on myosin, experiments that
measure the strength of the crossbridge in the presence and absence of acidosis are
necessary. Using a laser trap assay, others have performed such experiments, but only in
the absence of acidosis (89, 90). Here, once a single actomyosin crossbridge was formed
in the absence of ATP, the actin filament was pulled to apply a resistive load to the
myosin molecule. Because the laser trap acts as a spring, the farther the assembly is
pulled the more force is applied to the myosin, and the force at which the actomyosin
bond ruptures is recorded. These experiments are therefore feasible to do and could
provide evidence of the effect of acidosis on the force per crossbridge. If acidosis reduces
the force per crossbridge, the actomyosin bond should rupture at lower forces than in the
absence of acidosis. Again, this would provide a direct observation and quantification of
one of the putative effects of acidosis on myosin function.
To summarize our current understanding of the crossbridge cycle, myosin is the
molecular motor in muscle that cyclically binds to actin to produce force and motion. The
faster myosin moves through the crossbridge cycle, the faster muscle will contract, and
the more myosin bind to the thin filament, the more force is generated. Despite what we
know about myosin’s crossbridge cycle, we do not have a complete picture of how the
regulatory proteins and Ca++ affect myosin kinetics. We also don’t know how multiple
myosins work together to activate the thin filament. What follows is an explanation of the
thin filament regulatory proteins, how they regulate actomyosin binding, and how the thin
filament is activated. We then describe how specific perturbations affect this activation.
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Finally, we discuss what gaps exist in our knowledge, and possible experiments that
could help us fill those gaps.
Thin Filament Regulatory Proteins
Thin filament activation is required for a muscle to produce force and motion.
During muscle activation, Ca++ is released into the cytosol of the muscle cell and allowed
to bind to troponin. This leads to a slight structural movement of tropomyosin, a
filamentous protein wrapped around actin. Together, troponin and tropomyosin are the
regulatory proteins, so called because they regulate myosin’s ability to bind to actin.
During muscle activation, the shift in tropomyosin exposes myosin binding sites on actin,
allowing myosin to strongly bind to the thin filament and subsequently produce force and
motion.
Troponin has three subunits: the Ca++ binding subunit (TnC), the inhibitory
subunit that binds to actin (TnI), and a subunit that is bound to tropomyosin (TnT). TnC
is shaped like a dumbbell with eight major
helices, labeled A-H (figure 2.2). The first
four of the helices, A-D, are near the Nterminus and make up one of the ends of
the dumbbell. The N-terminus is
responsible for binding Ca++ during
activation which subsequently causes a
subtle movement of the helices B and C
where they ‘swing’ away from the helices

Figure 2.2. Structure of TnC. Helices are labeled A-H,
from N-terminus to C-terminus. The subtle movement
of the N-terminus is a crucial part of thin filament
activation. From Herzberg and James 1985 (54).
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A and D. This movement of the B and C helices exposes a hydrophobic patch on TnC
where TnI can bind.
TnI does not inhibit actomyosin binding directly; rather, TnI anchors tropomyosin
over myosin-binding sites on actin with its long C-terminus tail binding to actin. The Cterminus tail has two
particular segments
crucial for its function:
the inhibitory sequence
that binds to actin
(residues 96-116) and the

Figure 2.3. Structure of TnI. The C-terminus of Troponin I binds to actin in
the absence of Ca++, but binds to TnC in the presence of Ca++. Figure from
Vinogradova 2005 (123).

regulatory sequence (also called ‘switch’ sequence) that binds to TnC upon Ca++
activation (116-131) (44). Upon Ca++ binding and the subsequent movement within TnC,
the regulatory sequence swings up and binds to the hydrophobic patch on TnC (figure
2.3). With the C-terminus of TnI now detached from actin, tropomyosin is no longer
anchored to actin and can move on the actin surface, which can expose myosin binding
sites. In summary, the intricate motions of TnC and TnI control tropomyosin movement
which subsequently dictates myosin strong binding and thus the activation of the thin
filament.
The function of TnC and TnI may be altered during muscle fatigue. During
muscle fatigue, Ca++ levels may drop. In a rested, unfatigued muscle, Ca++ levels can be
high enough to saturate troponin. However, as fatigue ensues, the pCa level can decline
to approximately pCa 6 (71). This concentration is not adequate to saturate troponin and
may lead to submaximal forces. In addition, acidosis may impede the function of TnC
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and TnI. To tease apart which troponin subunit is most altered, chimeras of troponin were
created, where troponin subunits from both cardiac and skeletal fibers are isolated and
then mixed. For example, one chimera created in these experiments is TnC from cardiac
fibers combined with TnI from skeletal fibers. The results from these experiments
suggested that both troponin subunits are effected by acidosis, but TnC seemed to be the
most sensitive (6, 30, 86, 93). Further work showed that the first 41 residues of both
cardiac and skeletal TnC are responsible for this sensitivity (30). Further evidence of the
effect of acidosis on TnC was provided by isolating TnC and examining its ability to bind
Ca++ in the presence or absence of acidosis. The percentage of Ca++ bound to troponin
was measured at various Ca++ concentrations, and acidosis led to less Ca++ binding across
these Ca++ concentrations (93). Thus, an acidosis-induced reduction in thin filament
activation likely occurs due to direct effects of acidosis on TnC. Considering that the first
41 amino acids play a crucial role in TnC function, in the presence of acidosis, the
hydrogen ions may compete with Ca++ for the Ca++ binding sites on TnC (7, 8, 35).
Despite the evidence to suggest that acidosis predominantly affects TnC, some
data shows that the effect on TnI is more important (22, 24, 131, 133). Cardiac Tn is
more sensitive to acidosis than filaments with skeletal Tn, shown by a larger shift in the
pCa-force relationship (86). More specifically, slow skeletal fibers are less sensitive to
changes in pH, and this difference was hypothesized to be due to differences in TnI.
Experiments showed that replacing cardiac TnI with slow skeletal TnI resulted in an
attenuation of the effect of pH on cardiac fibers (131). By examining the amino acid
sequence of these TnI isoforms, the authors focused on one particular amino acid that
was different in the C-terminus. This amino acid is located at the 132nd residue on
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skeletal TnI and the 164th on cardiac TnC, which means this residue is located in the
inhibitory region of TnI, a crucial part of the subunit that binds to TnC’s hydrophobic
pocket when the Ca++ is bound. Therefore, this is an area that plays a large role in the
protein’s function. To test this, TnI was engineered where this one amino acid was
switched in both TnI isoforms and found that this caused slow skeletal fibers to be more
sensitive to acidosis (133) while cardiac fibers were much less sensitive to acidosis (22).
Interestingly, this one residue cannot account for all of the difference in acidosis
sensitivity across fiber type. This can be ascertained by carefully examining the TnI
amino acid sequence for slow skeletal, fast skeletal and cardiac fiber types. Both slow
and fast skeletal TnI have this ‘acidosis resistant’ residue, yet fast skeletal TnI is
significantly more sensitive to acidosis than slow skeletal TnI. Thus, this one residue
does not save fast skeletal TnI, and thus other residues or structures in Tn must account
for this acidosis sensitivity. Further work is necessary to find which residues are
responsible for these differences. Regardless of the precise mechanism, these chimera
and single point mutation experiments have provided the framework as to how the effects
of acidosis can be attenuated.
Ca++ Activation of the Thin Filament
Ca++ activation dictates force and velocity production. During a maximal
contraction in a fresh, unfatigued skeletal muscle, Ca++ levels are relatively high: almost
all of the troponins will have Ca++ bound at any given moment, assuming a binding
constant for Ca++-Tn of ~ 0.5 µM (93). This allows tropomyosin to move freely on the
actin surface, and allows myosin to bind to the thin filament. However, there are some
important cases where Ca++ levels aren’t at maximum levels. One example is during

26

muscle fatigue, where during prolonged intense contractions, Ca++ levels in the cytosol
drop (3, 130). This leads to a decrease in filament activation and thus a decrease force
and velocity. Another example of submaximal Ca++ levels during contraction are those
experienced in cardiac muscle. In each cycle of contraction and relaxation that occurs
with a heartbeat, maximal Ca++ levels are never reached. This means that during
successive heartbeats, the Ca++ concentration quickly slides up and down the steep
portion of the pCa-force relationship. As shown before, a typical pCa-dependent
relationship is shown in figure 1.3.
These data are fit to the Hill equation, shown here:
𝑦 = min +

max − min
1 + 10log(𝑝𝐶𝑎50−𝑝𝐶𝑎)𝑛

Where ‘min’ equals the minimum velocity, ‘max’ is the maximum velocity, ‘n’ is the Hill
coefficient, and pCa50 is the amount of Ca++ necessary to reach half-maximal velocity.
The first major outcome is the pCa50. The Ca++ concentration required to elicit
half-maximal velocity or force is termed pCa50 and is a measure of Ca++ sensitivity. A
lower pCa50 suggests more Ca++ is necessary to reach a given velocity or force;
conversely, a higher pCa50 suggests less Ca++ is necessary. Ca++ sensitivity is important
considering how steep the pCa-velocity and pCa-force relationship are: subtle changes in
the Ca++ concentration can drastically change work output of a muscle. Perturbations
within the muscle cell, drastically alter this relationship, where much more Ca++ is
necessary to reach a given force output (88). A possible method to examine the effect of
such perturbations on Ca++ sensitivity is to use the laser trap assay to directly observe
myosin interact with a regulated thin filament across a range of Ca++ levels. This can also
be done with a small ensemble of myosin interacting with one regulated actin filament.
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This would recapitulate in vivo muscle, as many myosins work together to pull on a
regulated actin filament.
The second major outcome from a pCa-force relationship is the cooperativity of
myosin molecules. The Hill coefficient, n, is an indication of this cooperativity. When n >
1, binding is said to be cooperative, where one binding event accelerates the rate of
subsequent binding events (45). In the case of the contractile proteins, this suggests that
one myosin binding event facilitates subsequent myosin binding. Cooperativity has four
main mechanisms: 1) coupling between the two Ca++ binding sites on fast skeletal TnC,
2) coupling between Ca++ binding sites down the thin filament, 3) myosin strong binding
inducing Ca++ binding to TnC, and 4) myosin strong binding inducing movement of
tropomyosin into an open state so other myosin can more easily (44).
There is some evidence for the first mechanism contributing to cooperativity,
though not by much. There is evidence that the two Ca++ binding sites on fast skeletal
TnC bind cooperatively, leading to a Hill coefficient of 1.2 (46). This mechanism isn’t
possible in cardiac TnC, which only has one Ca++ binding site. Interestingly, if skeletal
TnC is added to cardiac thin filaments, cooperativity is observed (4). Regardless of this
cooperativity, the first mechanism of cooperativity is not enough to explain the highly
cooperative action observed in fibers.
There is also evidence for the second mechanism, where Tn along the thin
filament are able to cooperatively bind Ca++. By using fluorescent probes on Tn, Ca++
was shown to bind cooperatively down the thin filament (46, 50). Other experiments
suggested this mechanism of cooperativity by performing partial extractions of TnC and
observing cooperativity decrease (10, 87).
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Like the first two mechanisms, the third mechanism likely plays a small role, but
there is evidence that myosin binding can cooperatively increase Ca++ binding to Tn,
Experiments using fluorescent probes on Tn (50) suggest that Ca++ binding to Tn is
influenced by myosin. Other experiments have tested this hypothesis using myosin
modified with BDM, which keeps myosin in a weakly bound state (93). However, some
have suggested that only rigor myosin have this effect, which leads to the question if this
mechanism would occur under physiological conditions (11, 39).
The fourth mechanism is most likely to have the biggest effect in generating
cooperativity and thus Hill coefficients greater than 1.5. This has been demonstrated
multiple times by either decreasing ATP or by increasing ADP (40, 48, 56, 104). The
former would increase rigor myosin, while the latter would increase M.ADP myosin,
both of which can strongly bind to the regulated thin filament and help neighboring
myosin to bind. Similarly, NEM modified myosin were used to activate the thin filament
(111). Additional evidence for the fourth mechanism comes from experiments with
partial TnC extractions: by removing TnC, the tropomyosin stays in the blocked state and
prevents myosin from communicating. Finally, creative experiments were done with
fluorescent S1 myosin, which were observed binding to a native myofibril. S1 bound to
the overlap region (of the thick and thin filament) four times more than the nonoverlap
region, suggesting that the myosin in the thick filament helped the fluorescent S1 bind to
the overlap region. These experiments were done with both rigor and M.ADP S1 under
high Ca++ and low S1 conditions. To further support myosin-myosin cooperativity, as S1
was increased in this experiment, the S1 would bind to the nonoverlap region in highly
cooperative manner (112). Thus, there is a large amount of evidence to suggest that
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myosin-myosin cooperativity is the biggest contributor to the highly cooperative nature
of the pCa-force relationship.
How cooperativity occurs is a dynamic and complex process and has been
difficult to characterize. Indeed, recent innovative approaches (29) and sophisticated
mathematical models (42, 84, 126) have tried to describe this phenomena quantitatively.
Why is it difficult to quantify and characterize cooperativity? This is because
cooperativity involves both elements of time and space, where myosin binding to actin is
short-lived (as short as 2 ms) and thus only activates the filament for a very short period,
and will only facilitate binding of other myosins that are nearby. Why is myosin
necessary to activate the thin filament? Previous work (52) suggested that tropomyosin
worked like a switch that could either be open, allowing myosin binding, or blocked,
preventing myosin binding. An alternative hypothesis suggests that tropomyosin explores
three states: blocked, closed, and open. In both models, tropomyosin blocks actomyosin
binding sites in the absence of Ca++. In the latter model, called the three-state model, Ca++
binding does not cause tropomyosin to completely open the actomyosin binding sites;
rather, it only slightly exposes them, and so this state is called the closed state. Finally,
when a myosin binds to actin, myosin pushes the tropomyosin to the open state. An
important note is that tropomyosin is dynamic, and that even in the absence of Ca++
tropomyosin has a finite probability of being in the open state. For example, previous
work has quantified this probability, showing that even in the presence of Ca++,
tropomyosin is in the closed state 75% of the time while it is in the open state 98% of the
time when myosin binds to actin (45, 81). This three state model is further supported by
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biochemical experiments (72, 81, 118), in vitro motility assay (62), fiber studies (111),
modeling (62, 81), and structural studies (19, 98, 108, 122, 125). Clearly, actomyosin
binding plays a crucial role in thin filament activation, but how does this effect other
myosin molecules? When one myosin pushes tropomyosin into the open state, this state is
propagated down the thin filament, where other actin monomers now have their binding
sites more exposed. To
understand cooperativity, the
distance down the filament that
tropomyosin movement is
detected is a crucial measure.
This, of course, depends on how
rigid tropomyosin is: if
tropomyosin is rigid like a metal

Figure 2.4. Cartoon of the 3-state model of thin filament
activation. Actin (light gray) and tropomyosin (dark gray) in the
blocked (B), closed (C), and open (D) state. Areas on actin where
myosin binds weakly (green) and strongly (red) are highlighted.
Figure from Gordon et al. 2001 (45).

rod, when one myosin binds to
actin the whole tropomyosin structure should be pushed to the open state. On the other
hand, if tropomyosin is soft and flexible, the open state may not even propagate down the
tropomyosin molecule for the next myosin. In reality, the data suggests that tropomyosin
is semi-rigid: experiments using the laser trap assay have shown that one myosin binding
can facilitate another that is approximately 110 nm away (62). However, other work has
shown that tropomyosin may be more flexible than previously thought, as determined by
its persistence length (77). Persistence length is a common measure of the stiffness of
filamentous proteins, where pieces of the beam that are closer together than the
persistence length are correlated and represented as part of a semi-rigid rod, while pieces
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farther apart than this threshold are not correlated. Previous findings suggest that
tropomyosin’s persistence length anywhere from 40-500 nm (62, 77, 80, 97, 103, 122).
Such various values make determining how far cooperativity is propagated down the thin
filament quite difficult. Furthermore, neither the term ‘persistence length’ or ‘cooperative
length’ capture the physiological complexity of cooperativity. Are all myosins within this
distance treated equally? For example, if the cooperative length was 100 nm, do both the
myosin 10 nm away and the myosin 90 nm away increase their chances of strong binding
to the thin filament? Or is the probability of a second myosin binding increased if it is
closer to the first myosin that is bound? Sophisticated mathematical models of thin
filament activation suggest the latter (126, 127), but experimental data with small
ensembles of myosin are necessary to confirm this, especially in the presence of
submaximal Ca++ levels. Such experiments would provide crucial information on how
both Ca++ and myosin strong binding play a role in thin filament activation. Additional
experiments in the presence of acidosis can explore this effect on cooperativity.
To successfully model thin filament activation and subsequent muscle output, a
universal model must 1) take into consideration many sets of data and be able to match
the data, 2) explain and match data across all scales of muscle, from the whole organ to
the single myosin, 3) be within the limits of current computational power, and, of course,
4) explain data across different activation conditions, such as various Ca++ levels, various
myosin concentrations, and various metabolite concentrations, such as ATP, Pi, etc.
Some models use Monte Carlo simulations to predict behavior on a sarcomere
level (14). This model is able to describe activation, even at low Ca++ levels (1).
Unfortunately, Monte Carlo simulations are computationally heavy, and can only model
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small parts of muscle (in this case, one thin filament). Further, this model has not been
tested in its ability to explain whole muscle findings or data with metabolic perturbations.
Other models are designed to explain whole muscle findings using molecular
inputs. For example, Tanner et al. developed a model that recapitulates the lattice
structure of muscle (116). They argue that this 3D model is better than a comparative 2D
model. Though informative, this model has also not been tested with metabolic
perturbations. In addition, a minor critique is that rate constants used in the paper come
from three different research groups. These rate constants were determined from
myofibril or muscle fiber data. Though reliable, these data are not determined through
direct observation. On the other hand, data collected from assay such as the laser trap
assay are from direct observation and can provide the most reliable picture of the actions
of thin filament activation on the molecular level.
Though many models exist, the model that seems to fit all of our criteria is created
by Walcott (126). This model has been tested with many sets of data across the scale of
muscle, especially with single molecule and small ensemble data sets (28, 62, 127). A
large benefit of this model is that this model uses findings from a specific cohort of
researchers (28, 62, 128) which ensures fidelity. This model uses the more computer
friendly partial differential equations (PDEs) to perform calculations, as opposed to
Monte Carlo simulations, which, while useful, can be computationally heavy because
they aim to characterize each molecule’s behavior at any given moment. Finally, and
possibly most important, this model can make predictions across all muscle scales, from
the single myosin molecule up to whole muscle.
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The R146G Mutation
A major goal of this work is to better characterize thin filament activation so that
we can apply that knowledge to muscle fatigue or diseases caused by point mutations. A
key way the knowledge can be applied is to compare the molecular details of activation
under normal conditions to situations that arise with mutated proteins. This is particularly
relevant to cardiac muscle, where a single point mutation can disrupt normal activation,
leading to abnormal force production and many times leading to lethal cardiomyopathies
(79). The most common mutations that lead to such drastic outcomes occur in the
sarcomere, including myosin, myosin binding protein C, tropomyosin, or troponin (79).
While the many common mutation sites within these three proteins are actively being
studied, one in particular, the R146G mutation in TnI, has been a quagmire and may
affect both myosin kinetics and Ca++ binding dynamics (12, 34, 60, 69, 70, 75, 114, 129,
132, 138). Considering this, we felt this particular mutation was worth examining further.
Cardiac Troponin Structure
Cardiac troponin is slightly different than the skeletal isoform discussed earlier.
The two major differences are that cardiac troponin C has only one Ca++ binding site on
the N-terminal, and that cardiac troponin I has 30 more amino acids in the N-terminal.
These 30 more amino acids cause a shift in the homologous structures. For example, the
inhibitory region of skeletal troponin I is located near amino acids 96-116, while the
inhibitory region of cardiac troponin I is located near amino acids 126-146. These places
our mutation of interest within the inhibitory region of cardiac troponin I. This particular
mutation involves a switch from a relatively large, charged arginine to the small,
hydrophobic glycine. Exactly how this alters the structure of TnI is difficult to say. As
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some have pointed out, many cardiomyopathic mutations are clustered in flexible regions
of proteins, which makes obtaining structural data with cryo-EM or crystallography quite
difficutl (12). This flexibility may lead to the mutation’s negative effects on myosin and
thin filament activation.
Effect of R146 on Myosin
Interestingly, the R146 mutation seems to affect myosin’s function, even at
maximal Ca++ activation. At maximal Ca++, myosin binding is expected to be the limiting
factor in force production (41). Yet, with this mutation, there is evidence that force is
reduced at maximal Ca++ (70, 129). Interestingly, these results are equivocal, where
others have shown no significant decline in force (114, 132). The discrepancy may be due
to differences in expression of the R146G mutation across transgenic experiments. James
et al showed that differences in expression level can alter the phenotype (60).
Specifically, mice that expressed a larger percentage of R146G relative to wild-type
troponin had a lower survival rate. The cause of the observed reduced force in (70, 129)
is difficult to explain, considering high Ca++ levels should fully activate troponin and
tropomyosin, and any limit in force would be due to a limit in myosin kinetics or
mechanics. Indeed, some have proposed that the R146G alters myosin’s crossbridge force
(129). This is surprising, as TnI interacting with or altering myosin’s function is
unexpected. Others have found that the cause and effect relationship is different: using
FRET, Zhou (138) measured the Ca++ dependence of the TnC-TnI interaction in both
wild-type and R146G filaments, and found that the presence of S1 myosin induced a
large shift in the pCa50 in mutant filaments but not in wild-type. These data suggest that
S1 somehow influences TnC-TnI dynamics in the presence of the R146G mutation.
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In addition to a decline in force, the mutation causes a decline in ATPase activity
at maximal Ca++ (70, 114), though others have found no decline in this measure (34,
129). The discrepancy in results does not seem to be due to differences in methods,
considering Lang et al. 2002 and Elliot et al. 2000 both used reconstituted thin filaments
in solution.
Finally, the R146 mutation has been shown to reduce peak velocity at maximal
Ca++ in a motility assay (12) but not in fiber assay from transgenic mice (60). Here, the
difference could be attributed to the overall percentage of R146G troponin. In a motility
assay, the percentage of any given protein can be easily controlled (in this case, 100% of
the troponin in the regulated thin filaments was mutated) while transgenic models rarely
achieve 100% inoculation. Though the percentages achieved in James 2000 (40-80%) are
a better representation of the expression levels in patients with this cardiomyopathy, the
decline in motility shown in Brunet et al. provides insight into how this mutation affects
force and motion. Brunet et al. propose a model where the R146G mutation contributes to
a very flexible TnI subunit. The result is incomplete inhibition of actomyosin binding in
the absence of Ca++ and incomplete activation upon Ca++ binding, suggesting the
mutation does not affect myosin directly.
Effect of R146 on Thin Filament Activation
The more obvious effect of a mutation in troponin is the effect on Ca++ sensitivity.
Indeed, the R146G mutation leads to an increase in the Ca++ sensitivity, indicated by an
increase in the pCa50, in ATPase measures either in solution (34, 114) or in isometric
fibers (129). Similar shifts in the pCa50 have been found in isometric force measures of
fibers from transgenic mice, transfected mice, and in fibers following a Tn exchange that
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contained the R146G mutation (60, 70, 114, 129, 132). However, there is data showing
that the R146G mutation has no effect on force in transgenic mice or following Tn
exchange (69). Finally, the shift in Ca++ sensitivity has recently been seen in the pCavelocity relationship as well (12). In addition to finding an increase in Ca++ sensitivity,
many have found that the R146G mutation is not sufficient to completely inhibit ATPase
at low Ca++ (34, 70) nor is it sufficient to completely prevent force production (69, 70,
114, 129).
What can explain the overall findings for the R146G mutation? How does this
mutation leads to enhanced ATPase and force at low Ca++ but reduced ATPase and force
at high Ca++? One model suggests that the R146G mutation leads to weaker bonds to both
actin (34) and to TnC (75). A weaker bond to actin under low Ca++ conditions would
increase the probability of TnI detaching from actin, allowing tropomyosin to move on
the actin surface and eventually will lead to a higher probability of myosin binding to
actin. A weaker bond to TnC, on the other hand, would lead to a lower probability of TnI
binding to TnC upon Ca++ activation. This may suggest that TnI is moving freely or TnI
may still be bound to actin, despite the presence of Ca++. Another possibility is that the
mutated TnI interacts with myosin under high Ca++ conditions. As stated earlier, this
interaction seems unlikely but there is evidence to suggest that the mutated TnI affects
myosin’s crossbridge force. If this TnI-myosin interaction is possible, the mutated TnI
may not only myosin’s mechanics, but also its kinetics. More specifically, experiments
examining the effect of the mutation on myosin’s on-rate as well as myosin’s duty cycle
would add to our understanding of this mutation. While determining the precise structure
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and dynamics of R146G TnI is very difficult, determining how the mutation affects
myosin kinetics can be easily examined in an in vitro motility assay.
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CHAPTER 3
METHODS
To achieve the aims of this project, the laser trap assay and the in vitro motility
assay were used. As alluded to before, in vivo studies as well as single muscle fiber and
motility experiments have led to our current understanding of working muscle. Though
informative, more precise techniques are needed to understand the molecular basis of thin
filament activation and muscle contraction. To achieve this, the laser trap can be used to
examine the molecular details of the contractile proteins. Single muscle fibers contain
billions of myosin molecules as well as a complex array of other proteins, but the laser
trap assay allows for the direct observation of a single myosin molecule interacting with a
single actin filament. Here, we can directly observe specific steps of the crossbridge
cycle, a feat not achievable with muscle fibers. The laser trap assay can be used to better
understand actomyosin binding kinetics, force production of single myosin molecules,
and activation of the regulated thin filament (5, 15, 25, 29, 37, 62, 121). The laser trap
assay was used to directly observe, on the nanometer and millisecond scale, the binding
and force-producing capacity of an individual and small ensembles of myosin.
Using this assay, we first examined the effects of Ca++ on a single myosin’s
ability to bind to a regulated thin filament. We measured the binding events per second as
well as each event’s duration. Second, we examined how a small ensemble of myosin
interact with a regulated thin filament. We directly observed the how a small ensemble of
myosin work together in a cooperative fashion to pull on the actin filament to generate
force and motion in a Ca++ dependent manner. These experiments enabled us to
recapitulate the pCa-force relationship on the molecular level. In addition, this particular
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experiment was one of the best representations of in vivo muscle because of our use of a
small ensemble at relatively high (100 µM) ATP concentrations.
The in vitro motility assay is designed to observe unloaded velocity of actin
filaments as they are propelled by myosin in a variety of conditions. In our experiments,
we manipulated ATP and Ca++ and measure the resulting velocity. This technique, called
a “rigor activation” assay, will provided insight into thin filament activation. This is
because Ca++ affects regulatory protein dynamics, while ATP affects myosin’s kinetics,
in particular, how long myosin stays bound to actin in the rigor state. Because both Ca++
and myosin strong binding play a role in thin filament activation, this assay provides
insight into the dynamics of each.
We also used the in vitro motility assay to examine the effects of a particular
troponin mutation, R146G, on thin filament activation and myosin kinetics. To examine
these effects, we first measured unloaded velocity in a Ca++ dependent manner and
generated a pCa-velocity relationship. We then performed a duty cycle experiment,
where the number of myosin heads available to the regulated thin filament was
manipulated and the velocity of each filament was measured. These data were then fit to
a duty cycle equation (120):
𝑉 = 𝑉𝑚𝑎𝑥 ∗ (1 − (1 − 𝑓)𝑁 )
to determine the percentage of time myosin is strongly bound to the filament. In
this equation, V is the measure velocity of a filament, Vmax is the maximum velocity, f is
the duty ratio, or the percentage of time myosin is strongly bound to actin, and N is the
number of myosin heads interacting with the filament. As V changes as a function of N,
and the data can be fit, where Vmax and f are determined by the fit. Finally, we then
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manipulated ATP in a motility assay to examine if the R146G mutation alters myosin’s
ADP-release rate, which directly affects myosin’s on-time.
Overall, the proposed experiments have allowed a better understanding of the
molecular details of thin filament activation. The experiments also provide insight into
how thin filament activation is altered by troponin mutations. This will set a foundation
for future work that can examine this mutation and others that lead to cardiomyopathies
and the development of therapeutics to combat the negative effects associated with the
mutations.
Laser Trap Assay
Background
The laser trap assay was used to directly observe either single myosin or a small
ensemble of myosin generate force and motion by interacting with a thin filament. To do

Figure 3.1. Cartoon of the 3-bead assay. Myosin is randomly oriented on the microscope slide surface,
occasionally located on a pedestal bead. A bead-filament-bead assembly, trapped by laser light, is put in close
vicinity to the pedestal so single molecule interactions can be observed and measured. Figure courtesy of Mike
Woodward.

this, a powerful, densely focused beam of light traps two 1 μm glass beads which are then
attached to each end of a thin filament. This bead-filament-bead set up, or “dumbbell” set
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up, is positioned near a 3 μm bead on the microscope slide surface that is sparsely coated
with myosin (figure 3.1). This set up enables one myosin molecule or an ensemble of
myosin molecules to interact with the actin filament. As myosin pulls on the thin
filament, the position of one bead is detected by a quadrant photodiode, which can
discern nanometer and millisecond motions, and the force exerted on the filament by the
myosin can be calculated.
Hardware and Software
The optical light path used to form the laser trap is very similar to that previously
described (28) with minor changes. Briefly, a 5 W, infrared (1090 nm) laser beam (SPI
Lasers, Santa Clara, CA) is timeshared between two locations at 10 kHz using two
orthogonally (x and y) oriented acousto-optic deflectors (AODs) (DTD-274HA6, Intra
Action, Bellwood, IL). An AOD serves to deflect a beam of light as a function of the
radiofrequency transmitted through the medium. By altering the frequency, the beam of
light and thus the trapped bead can be steered. The AOD is driven by a custom-built
digital controller (Elliot Scientific, Hertfordshire, United Kingdom) that interfaces with a
personal computer via a field-programmable gate array card (PCI-7830R, National
Instruments, Austin, TX) and custom software developed using the real-time module of
LabView version 8.6 (National Instruments).
Displacements of one of the trapped beads were determined by imaging the
interference pattern of the bead onto a quadrant photodiode (QD) (G6849, Hamamatsu
Photonics, Hamamatsu City, Japan) conjugate with the back focal plane of the condenser
(32). This displacement signal was digitized via a National Instruments data acquisition
module (USB 9162) and collected at 5 kHz. Coarse movements of the microscope stage
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were made using a manual micrometer-driven stage with a capacitive servo-feedback
piezoelectric substage (Nano-Bio200, Mad City Labs, Madison, WI) that can generate
nanometer movements for fine control. The fluorescent thin filament was then visualized
using an intensified CCD camera (Stanford Photonics, Palo Alto, CA) while
simultaneously visualizing the silica beads in bright field using a CCD camera, which
interfaced with the PC.
Trap Stiffness Calibration
The force of the laser light applied to a 1 µm bead behaves as a simple linear
spring, where F = k * x, where F is the force, k is the spring constant of the trap (or
stiffness) and x is the distance the bead is from the center of the trap. The stiffness of our
optical trap was determined two different ways: the equipartition method and the power
spectral density method. The equipartition method relies on the relationship between
thermal energy and the spring energy. The thermal energy for one-dimensional diffusion
is ½kBT, where kB is the Boltzmann constant and T is the temperature of the
environment. The spring energy of a bead in an optical trap is ½kx2, where x2 is the
variance in the bead’s position. Therefore, we can derive:
𝑘𝑡𝑟𝑎𝑝 =

𝑘𝐵 ∗ 𝑇
𝑥2

We measured the variance of the bead’s position and determine the stiffness of the trap.
To confirm our calculations, we used the power spectrum density. For a sphere in
solution, the drag coefficient, γ, is calculated as:
𝛾 = 6∗𝜋∗ 𝑛∗𝑟
Where n is the viscosity of the solution and r is the radius of the bead. The power spectral
density gives the function:
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𝐹(𝑡) =

2∗

𝜋2

𝑘𝐵 ∗ 𝑇
∗ 𝛾 ∗ (𝑓 2 + 𝑓𝑐 2 )

Where fc is the corner frequency, which is equal to:
𝑓𝑐 =

𝑘𝑡𝑟𝑎𝑝
2∗ 𝜋∗𝛾

And thus, the stiffness of the trap, ktrap, can be calculated.
Proteins
Whole myosin and actin were purified from chicken pectoralis muscle based on
previous methods (78, 92). SDS gels and High Performance Liquid Chromatography
(HPLC), tools used to separate proteins by size and charge, demonstrated the high purity
of the proteins. Myosin was stored in glycerol (50% v/v) at -20°C for up to 1 year. The
purified actin filaments were fluorescently labeled and stabilized with TRITC/phalloidin
and coated with biotin and stored at 4°C. Wild-type skeletal troponin was purchased (Life
Diagnostics, West Chester PA), while troponin variants will be generously provided by
our collaborator Dr. Tomo Kobayahsi at the University of Illinois. Dr. Tomo Kobayashi
prepared and provided troponin as described here. Recombinant mouse cardiac TnI, TnC,
and TnT was inserted into pET3d vector and expressed using BL21(DE3) cells.
Expression of the correct sequence was confirmed by DNA sequencing. The subunits
were purified, reconstituted, and frozen in liquid nitrogen. The troponin variants were
divided into single experiment sized aliquots, snap frozen in liquid nitrogen, and stored at
-80°C until the day of the experiment.
Solutions
On the day of an experiment, the purified chicken pectoralis myosin was diluted
to 200 μg/mL in myosin buffer (300 mM KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM
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MgCl2, 1 mM DTT). An equimolar concentration of purified chicken pectoralis actin was
added to this solution, in addition to 1 mM ATP. This solution was centrifuged at
400,000 g for 20 minutes to separate live myosin from ‘dead-head’ myosin that cannot
hydrolyze ATP. The ‘dead-head’ myosin bind to the actin and pellet, while the live
myosin stays in solution. This solution was extracted and diluted so the myosin was at a
final concentration of 0.1 µg/mL for single molecule experiments or 10 µg/mL for
experiments with small myosin ensembles.
To create reconstituted regulated thin filaments, on the day of an experiment 1
µM actin was mixed with 0.25 µM troponin and 0.25 µM tropomyosin and allowed to
incubate for 3 hours. This solution was then diluted to bring the actin concentration to 10
nM. Full reconstitution and thus full regulation was confirmed by performing an in vitro
motility assay with 100 µg/mL myosin and the regulated filaments at pCa 10. After the 3hour incubation, the actin was diluted in a low salt actin buffer (25 mM KCl, 25 mM
Imidazole, 1 mM EGTA, 4 mM MgCl2, 1 mM DTT) to 10 nM. BSA was diluted in actin
buffer to 0.5 mg/mL. The 1 µm trapping beads were incubated with 0.5 mg/mL
neutravidin and allowed to incubate for 3 hours. After 3 hours, the beads were diluted in
actin buffer and sonicated to remove excess neutravidin that did not bind tightly to the 1
µm beads. This washing process was repeated and the beads were then diluted in 500 µL
of actin buffer.
The final buffer for the laser trap assay was composed of actin buffer with
experiment-specific additions. For pCa-force experiments, a calculated amount of Ca++
was added to reach a specific Ca++ concentration and 100 µM of ATP was used. For
single molecule binding experiments that examine on and off rates, 10 µM of ATP will
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be used. For all experiments, the ionic strength was held constant at 95 mM by adjusting
the amount of KCl added to the final buffer. The pH of the final buffer was set to 7.4.
Buffer recipes will be determined using a computer algorithm with known chemical
binding constants, with adjustments for temperature, pH and ionic strength (WinMaxC)
(52). All final buffers contained an oxygen scavenger system (1725 mg glucose, 75 mg
glucose oxidase, and 14 mg catalase) to prevent photobleaching of the actin filaments.
Laser Trap Assay Protocol
Myosin was added to the flow cell and allowed to bind to the nitrocellulosecoated surface for 2 minutes. BSA was flowed in and allowed to incubate for 5 minutes
to ensure actin does not attach to the nitrocellulose surface. While this incubation occurs,
the neutravidin beads were sonicated to break apart any coagulation. 3 µL of the beads
were added to 181 μL of final buffer. This aliquot was vortexed to ensure a homogenous
mixture of beads. 8 μL of the 10 nM labeled actin and 4 µL of each regulatory protein at
5 µM was added to this final buffer. The flow cell was placed on the microscope. Finally,
the final buffer was added to the flow cell.
In the flow cell, we trapped 2 of the 1 µm beads. A labeled, regulated, biotin
coated actin filament was secured between these two glass beads. Once a bead-actin-bead
complex was assembled in the laser trap, the filament was pulled taught, with a
pretension of 4 pN. The complex was lowered to a 3 µm bead coated with myosin. As the
QD determines the position of one of the neutravidin beads, actomyosin activity can be
observed. Actomyosin activity is confirmed by a directional displacement of the bead
from the laser trap, as determined by the QD. Once activity is observed, a 5 second
recording was taken.
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Data Analysis
The positional data of the 1 µm bead was measured in mV, which was converted
to nanometers after an internal calibration. For the data collected with a small myosin
ensemble, the data was then converted to forces, measured in pN, by multiplying the
nanometer displacements by the stiffness of the laser trap. In this way, we determined the
force produced by a small myosin ensemble.
To objectively detect single molecule events, an analysis called the Page method
was used (66). Essentially, this method looks for a decrease in variance in the signal,
which occurs when myosin strongly
binds to actin. If this decrease in
variance lasts long enough, the
program detects it as an event. More
specifically, the original signal is
corrected to zero. The program then
examines each point and calculates
the probability of the data point
being part of an event based on how
far the point is from zero. If the
probability is relatively high, a value is
added to a cumulative sum, whereas each

Figure 3.2. Example of the Page method. Single
molecule recordings were examined using the Page
Method. A sliding window is used to determine the
variance of the window. A low variance will lead to a
cumulative sum. An event is counted once the
cumulative sum reaches a predetermined threshold.

succeeding point that has a high probability
will also add to the sum. Once this sum reaches a pre-determined threshold, the program
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recognizes the data points to be part of an event. A sample trace and the corresponding
cumulative sum is shown in figure 3.2.
For force measurements with small myosin ensembles, each recording was
analyzed with a custom Matlab computer program. A brief description of the program is
as follows: first, the program examines all the data and determines the baseline of the
trace, where myosin and the thin filament are not bound. The program then examines
each data point in the file, checking if it is at least 8 nm above the baseline. The 8 nm
threshold is based on previous literature suggesting that when myosin binds to actin, it
generates a powerstroke that is at least 8 nm (15, 119). Therefore, this is the first criteria
to see if myosin has bound to actin. This minimum 8 nm displacement must occur for 10
consecutive milliseconds for the program to determine that a binding event has occurred.
The 10-millisecond criterion is based on the expected duration of a single myosin-actin
interaction. This interaction is dependent on the length of the actin-myosin-ADP state and
the myosin-actin rigor state. Assuming an ADP release rate of 100 to 350 per second (5,
128) and an ATP binding rate of 2 to 7 x106 * s-1 * M-1 (5, 91), approximately half of the
single myosin-actin binding events should last 10 ms or longer at our experimental
conditions of 100 µM ATP. Once the program determines that an event has occurred, the
time at which the event began is determined. In addition, if this is not the first event in the
recording, the program calculates how much time has passed since the previous event
ended. This is a useful measure that provides insight into the binding frequency, a
measure that is expected to change under the various conditions tested, particularly the
different Ca++ concentrations. Finally, when the event has ended, determined when the
recording has dropped back down to baseline, the duration of the event is calculated. In
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addition, the program examines the event and finds the 10 ms region that contains the
highest average mV signal. This average is then converted to pN and this peak force is
recorded. Thus, overall, the program can determine when an event occurs during a
recording, and then determines the duration and peak force of each event.
Some of our experimental conditions, including single myosin molecule
experiments or conditions with low Ca++ (pCa 9), required a different analysis strategy.
Under these conditions observing distinct single myosin-actin binding events in the
recording is difficult. However, actomyosin
binding significantly reduces the noise in the
force recording (figure 3.3). This occurs due
to the stiffness of the myosin-actin bound,
which reduces the movement of the actin
filament and thus the detected 1 µm bead.

Figure 3.3. Example of capturing events with
Brownian motion. During a recording, the signal of
the 1um bead is noisy (n) but during a myosinactin binding event (e) the variance drops
significantly. Figure from Veigel and Molloy (121).

Again, an in-house Matlab program will
examine the force recordings to determine

when an event has occurred. This program is very similar to the one used for myosin
ensembles, except instead of using an 8 nm displacement as a criterion, we will use a
70% drop in the variance of the signal. This cut-off was determined based on our current
estimates of the myosin-actin stiffness of 0.3 pN/nm and the expected decrease in the
variance based on this stiffness. Further, preliminary experiments have shown that this
threshold works well, as data recordings showed events, while control recordings (ones
where a recording was collected with the dumbbell set up positioned away from a 3 µm
pedestal bead and therefore where no myosin-actin binding could occur) showed no
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events. Though force measurements were not taken with this program, the duration and
time between can be measured as before. Therefore, we can gain insight into the on and
off rate of a single myosin molecule under many different conditions.
A critical measure for laser
trap experiments is the height of
the dumbbell set up relative to the
pedestal bead. Knowing that the
thin filament is close enough to the
pedestal bead to allow myosin
binding is important as this can
affect the frequency of myosin
binding; this value must be
consistent from one condition to
another. Therefore, during a

Figure 3.4. Determination of trap height. Top: Images taken of
the 3 µm pedestal bead at different heights in the laser trap
assay using a brightfield camera. Bottom: Calculating the airy
disc created by the pedestal bead shows that the radius is
linearly related to the z-position in the laser trap.

recording we recorded a bright field image of the 3 µm bead. The height of the dumbbell
set up was determined by analyzing the airy disc diffraction pattern of the 3 µm bead.
This analysis can be used to determine axial position of micrometer particles (136). We
have applied this technique to our microscope and took approximately 30 images at
known heights, from 2.5 µm to 4.5 µm, and established a linear relationship between the
airy disc radius and its height (figure 3.4). These heights were recorded by driving the 3D
piezoelectric stage with nanometer resolution. A custom Matlab program was then
written to calculate future images based on our standard curve. Testing the model with
additional images at known heights showed that the model was accurate within 100 nm.
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Our data collected at high Ca++ shows that heights up to 3.5 µm above the surface allow
actomyosin binding, but heights above this do not. As stated earlier, some conditions
resulted in very discrete and scarce events. Therefore, some data recordings may show no
events at all, but if the corresponding height is within 3.0 to 3.5 µm, the data recording
was considered in the final analysis. Conversely, if the file is collected above 3.5 µm, the
data recordings were discarded.
Statistical Analyses
Histograms were generated for all experiments performed with a small ensemble
of myosin, showing the relative frequency of forces, durations, or time between events.
These measures were not normally distributed (28) and therefore a nonparametric
Kruskal-Wallis analysis of variance was performed to identify significant differences
across conditions, with differences identified using the method of Dunn (31).
For our experiments examining on and off rates of single myosin binding events we used
a one-way ANOVA comparing the different pCa concentrations. All statistical
procedures will be performed in SigmaPlot v11.0 (Systat Software, San Jose, CA) with
the alpha level set at p < 0.05.
Mathematical Model
A major goal of this dissertation was
to deconvolve the role of Ca++ and myosin
strong binding during thin filament
activation. To do this, we compared our
single molecule binding results with our
small ensemble results using a mathematical
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Figure 3.5. Cartoon of the 4-state kinetic model.
Myosin transitions from a weakly bound state (1) to a
strongly bound state (2). It then releases ADP,
entering a rigor state (3). ATP binds to myosin,
causing actomyosin dissociation (4).

model. This mathematical model incorporates a four-state kinetic model of the
crossbridge cycle (figure 3.5), with global and local coupling. Here, global coupling
refers to myosin molecules that affect each other’s kinetics through the thin filament. For
example, as a leading myosin pulls on the actin filament, a trailing myosin will feel this
pull, release ADP and subsequently release actin. This load-sensitivity of myosin is well
documented (47, 110, 121). Local coupling refers to myosin’s ability to influence
neighboring myosin and their ability to bind to the thin filament. The model employs a
flexible chain model, where tropomyosin is treated as a flexible chain that can be
distorted by myosin strong binding. The model depends on two key parameters: ε(Ca++),
the single myosin molecule transition from weak to strong binding as a function of Ca++
relative to the weak to strong transition rate in the absence of the regulatory proteins, and
ℓ, the coupling distance, such that two myosin within this distance that are strongly
bound to the thin filament completely activate the area of the filament between them, but
act independently if they are separated by a distance greater than ℓ. The model has fit
data from multiple scales, including single molecule, small ensemble, and motility data
(28, 126-128). In previous work, this model has assigned ℓ to equal 400 nm. Note that
this is not the same as the cooperative unit length, as ℓ only implies partial activation. For
example, in this model, unattached myosin that are close to a strongly bound myosin are
much more likely to bind than myosin that are farther away (but still within 400 nm). We
assumed that this ℓ is independent of Ca++.
The parameter ε is defined with the following equation:
𝜃
ε = ε1−𝜃
𝑚𝑖𝑛 ∗ ε𝑚𝑎𝑥
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where θ is the fraction of Tn bound to Ca++. This equation relates troponin’s binding of
Ca++ to myosin’s ability to bind strongly to the thin filament. From previous work, we
have estimated εmin to be 0.006 and εmax to be 0.5 (126). This equation is cleverly
designed: if θ is near its maximum of 1, εmin goes to 1 while εmax goes to 0.5. Completing
the equation results in ε = 0.5, suggesting that even in saturating Ca++, myosin only binds
half as well to regulated actin as it does to unregulated actin. Conversely, when Ca++ is
low, εmin goes to 0.006 while εmax goes to 1, so that completing the equation would result
in ε = 0.006. Thus, myosin’s ability to bind to regulated actin can be mathematically
modeled using the myosin binding rate to unregulated actin and θ, the fraction of
Troponins bound with Ca++.
We assume that Tn binding to Ca++ is fit by Michaelis-Menten and is determined
by the equation:
θ=

[𝐶𝑎++ ]
𝐾 + [𝐶𝑎++ ]

Considering our assumptions, the only parameter that determines ε(Ca++) is K, TnC’s
affinity to Ca++.
In Vitro Motility Assay
Background
In the in vitro motility assay, a nitrocellulose-coated coverslip is secured to a glass
microscope slide, creating a ‘flowcell’. Isolated myosin in solution is pipetted into the
flowcell and adhered to the nitrocellulose. Fluorescent actin filaments are then flowed in,
and the myosin on the surface can strongly bind to filaments (figure 3.6). When
regulatory proteins are used, they are flowed in and allowed to incubate with the actin for
seven minutes to ensure complete reconstitution of thin filaments (17, 57). Finally, the
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motility buffer is added, with the appropriate pH and Ca++ conditions, as well as ATP to
drive crossbridge cycling.
The fluorescent filaments are visualized as myosin propels them across the
surface. The filament movement can be observed and recorded, and the velocities can be
determined by measuring the distance traveled and the frame rate of the recording
camera.

Figure 3.6. Cartoon of in vitro motility assay. Schematic of actin filaments (white) moving a surface of myosin
molecules (orange). Figure courtesy of Mike Woodward.

The hardware and software, proteins, solutions, and assay are all similar to or
encompassed by those of the laser trap assay. What follows is a brief description of the
assay with key differences from the laser trap assay discussed.
Proteins
All proteins used in the motility assay are exactly the same as described above.
Solutions
Like the laser trap assay, myosin was ridded of dead heads and diluted, this time
to 100 µg/mL for most experiments (the duty cycle requires a range from 5 to 100
µg/mL). The final buffer was the same as before except 1% methylcellulose was added, a
crowding agent that keeps filaments near the myosin-coated surface, and 2 mM ATP. On
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the day of the experiment, actin was diluted to 10 nM as before, but this time in the
absence the regulatory proteins, which was incorporated directly in the flowcell. The day
of the experiment, troponin and tropomyosin was diluted to 0.75 μM and 0.25 μM,
respectively, and mixed in AB with additional KCl. Further, 100 nm excess troponin and
tropomyosin was added to the motility buffer to ensure complete regulation of the thin
filaments (17, 57). For the large ensemble experiments, both ATP and Ca++ were
manipulated in the motility buffer. For the pCa-velocity experiments comparing wildtype and R146G troponin, the Ca++ was manipulated. For the ATP experiments, the ATP
concentration was manipulated for both the wild-type and the R146G mutation.
In Vitro Motility Assay
As before, myosin was added to the flowcell followed by BSA, which was
allowed to incubate for one minute. After one minute, vortexed unlabeled actin is flowed
in, which is another preventative measure against any ‘dead-head’ myosin. All myosin
will bind to the unlabeled actin, but after ATP is added 30 seconds later, the live myosin
will dissociate from the unlabeled actin. Additional ATP was added to ensure all live
myosin have released the unlabeled actin. Labeled actin was then added and allowed to
bind to the myosin for one minute. Labeled actin was again added, and incubated for
another minute. The regulatory proteins were then added and allowed to incubate with the
labeled actin for at least seven minutes. Finally, the motility buffer with the appropriate
level of Ca++ and ATP was added.
Hardware and Software
Labeled actin velocity was visualized with an ICCD camera (XR/MEGA-10EX™
S30, Stanford Photonics Inc. Palo Alto, CA). This camera is attached to a Nikon Eclipse
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Ti® inverted microscope with a 100x, oil-coupled, 1.4NA objective. Video frames were
acquired through an Epix-LVDS frame grabber (Epix, Inc., Buffalo Grove, IL) and
controlled using Piper Control™ software (Stanford Photonics, Inc. Palo Alto, CA).
TRITC filters (Thor Labs, Newton, NJ) are incorporated into the optical path to excite
and visualize the filament on the ICCD camera. The flowcell was maintained at 30°C
with an objective temperature controller (20/20 Technologies Inc. Wilmington, NC). For
each flowcell, three videos of different fields were recorded to get a sufficient sample of
filament velocity, at 10 frames per second for 30 seconds.
Regulated Thin Filament Velocity Analysis
Each video was analyzed using the ImageJ plugin WRMTRK, which skeletonizes
each filament and determines distance traveled per unit time. This program tracks the
filaments that fit the chosen parameters and output an average velocity for each field. Our
parameters are as follows: to be considered moving, a filament must be at least 0.5 μm
long and travel for at least three seconds.
Each experimental condition was performed at least three times. Each video
typically captures 50-150 filaments. For the pCa-velocity measures, the data for each
troponin variant was fit to the Hill equation to generate parameters (pCa50, Hill
coefficient) for inferential statistics. Goodness-of-fit was determined with the R2 value.
Significant differences in the Hill coefficient and the pCa50 were determined in a one-way
ANOVA. For the duty cycle experiments, the data were fit to equation
V = Vmax * (1 - (1 – f)N)
where V is velocity, f is duty ratio, N is number of myosin heads (120). The major
output, f, was statistically compared between the wild-type and R146G mutation by
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comparing the value and the standard error to the fit. Similarly, the ATP experiments
were fit to an exponential and the Km was statistically compared between the wild-type
and R146G mutation by comparing the value and the standard error.
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CHAPTER 4
RESULTS
We characterized thin filament regulation on the molecular level by directly
observing single molecule interactions between myosin and a regulated thin filament in a
three-bead laser trap assay. This is the first time, to our knowledge, that single myosin
binding has been detected with a regulated thin filament in the three-bead laser trap
assay. With a single myosin, our main measure was frequency of binding, which
increased as Ca++ levels were increased. We then observed a small ensemble of myosin
interact with a regulated thin filament and measured force, duration, and the time
between events. The measurement of force, duration, and binding frequency of a small
ensemble of myosin interacting with a regulated thin filament is a novel achievement and
is a key step in bridging the gap in our understanding of single myosin kinetics to single
fiber and whole muscle actions. Again, our measures were a function of Ca++, where
force and duration increased and the time between events decreased as Ca++ was
increased. Finally, we measured velocity as a function of Ca++ and ATP. In these
experiments, high Ca++ produced velocities that follow a typical Michaelis-Menten
relationship, while at low Ca++ there exists an ideal ATP level to initiate velocity and thus
thin filament activation. In addition to our measures for thin filament activation, we
tested the R146G Tn mutation in the in vitro motility assay. Our pCa-velocity results
agree well with previous pCa-force and pCa-ATPase data, showing an increase in Ca++
sensitivity. We then teased out details of myosin’s kinetics, where the mutant was shown
to reduce myosin’s duty cycle and reduce myosin’s ADP release rate.
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Effect of Ca++ on Single Myosin Binding
We first tested the effect of Ca++ on thin filament activation by measuring the rate
of binding between a single myosin and a regulated thin filament in the three-bead laser
trap assay. At pCa 4, the binding rate was 0.85 events per second, and this rate slightly
increased to 1.11 at pCa 5, but then dropped to 0.45 at pCa 6 and then 0.23 at pCa 7
(table 1). Binding events were not detected at pCa 9, despite over 100 recordings totaling
more than 9 minutes. Therefore, we have included a value for pCa 9 published previously
for comparative purposes (62). These data are summarized in table 1. Sample traces show
either many events (pCa 4) or very few events (pCa 7) depending on the Ca++
concentration (figure 4.1). The rates achieved at pCa 4 and 5 are about half of rates
achieved with an unregulated thin filament (2.2 events per second), in agreement with
other work that has examined single molecules interacting with a regulated thin filament
(29).
In our experimental set up, placing the thin filament above the 3 µm mogul so that
myosin can bind is crucial. If the filament is too high in the experimental chamber,
myosin will not be able to reach the filament. To be sure that our low binding frequency
at low Ca++ was not simply due to this experimental error, we measured the height of the
actin filament under different Ca++ concentrations. This was done by taking an image of
the 3 µm bead and using the airy disk to determine height. We found that the height
across conditions was not significantly different (figure 4.2). We also found that the step
size and attachment time of binding events were not significantly different across pCa
levels (figure 4.3 and 4.4)
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Effect of Ca++ on Binding of a Small Ensemble of Myosin
We then tested the effect of Ca++ on the ability of a small ensemble of myosin to
bind to and generate force against a regulated thin filament in the three-bead laser trap
assay. These experiments could shed light upon cooperativity in muscle, where one
myosin’s binding to actin increases the probability of a nearby myosin binding. Based on
our myosin concentration and estimates of myosin availability, we suspect 6 to 8 myosin
heads were available to bind to the regulated thin filament (27). Hundreds of events were
recorded and plotted in a histogram (figure 4.5). At pCa 5, a wide distribution of forces
was generated, from 0.2 to 10.8 pN, suggesting that an event can be composed of either a
single head binding and releasing, multiple heads binding and then releasing, or multiple
heads binding, cycling multiple times, and then releasing. As the Ca++ was reduced to
pCa 6, 6.5, and 7 the peak forces decreased to 9.4, 5.0, and 2.8 pN, respectively. An
analysis of the data using the non-parametric Kruskall-Wallis ANOVA followed by
Dunn’s post hoc tests found no significant difference between pCa 5 and pCa 6, but did
see a difference between pCa 6 and pCa 6.5 as well as pCa 7. The comparisons are
summarized in table 4.2. The duration of events also had a broad distribution and
decreased with reduced Ca++ levels, coinciding with the force values (figure 4.6). Indeed,
the relationship between force and event duration form a linear relationship (figure 4.7).
In addition to measuring force and duration of each event, we also measured the
time between events (figure 4.8). This information provides insight into the strong
binding of the first myosin molecule. We prefer the measure of time between events over
binding frequency with the small ensemble data. This is because an “event” with small
myosin ensembles can include many actomyosin interactions, especially those events that
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produce large forces. Therefore, the time between events can provide insight into the rate
of binding of the first myosin molecule at the start of any event, regardless of the event’s
peak force and duration. At pCa 5 the distribution of time between events was dominated
by short times: approximately half of the time another event occurs within 100 ms. As the
Ca++ is reduced, this percentage drops, and at pCa 7 often more than a second would pass
before another event occurred. As the Ca++ was reduced to pCa 9, events became very
infrequent, where the time between events was often 5 seconds or more. We were able to
use the event duration data with the time between events data to calculate the percentage
of time where at least one myosin head was strongly bound. At pCa 5, this value was
31%, but it decreased to 10% and 2% at pCa 6 and 7, respectively.
Effect of Ca++ and ATP on Binding of a Large Ensemble of Myosin
Finally, we performed the in vitro motility assay with regulated thin filaments and
measured velocity as a function of Ca++ and ATP (figure 4.9). This method can provide
insight into the importance and role of Ca++ and myosin in thin filament activation. At
ATP levels <60 µM, the filaments were motile and the velocity was not different across
pCa levels. The most logical explanation for velocity at low ATP is thin filament
activation through myosin rigor binding. One myosin binding pushes the tropomyosin
into open state, revealing additional myosin binding sites on actin nearby. The activation
here is slightly different than that which occurs under physiological conditions because
the ATP is low. Because the ATP concentration is low, the initial myosin binding event
lasts a considerable amount of time, providing ample time for nearby myosin molecules
to bind to the regulated thin filament. Thus, rigor activation occurs at an ATP
concentration where heads are bound long enough to enable nearby myosins to bind, but
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short enough to allow processive movement. As the ATP was increased, however, the
velocities diverged in a Ca++ dependent manner. For example, at pCa 9, filaments ceased
to move, but at pCa 4 the filaments approached maximum velocity. The peak velocity for
each pCa level was widely distributed, with the largest difference between successive
Ca++ concentrations existing between pCa 6.5 and pCa 7.
Mathematical Model
The mathematical model can be used to determine TnC’s affinity for Ca++ in all
three experiments (single molecule, small ensemble, large ensemble). We can also test
the model to determine if a coupling distance of 400 nm is appropriate. The single
molecule experiments don’t have coupling, and therefore provide a clear picture of the
role of Ca++ on myosin’s weak to strong transition rate. The rates we observed were very
low (~1 event per second) compared to the transition rate observed in solution (~40/s)
(68, 94). This is most likely due to fluctuations in the thin filaments position relative the
single myosin molecules and not an effect on the myosin’s kinetics per se. When
correcting for this, the data are well fit by our model (figure 4.10) (see equations in
Methods: Mathematical Model), and generate a value for K of 0.216 ± 0.055 µM.
The small ensemble experiments have both Ca++ and myosin strong binding
activation. Here, we can use the model to separate the effects of these two activators, as
well as test the model’s assumption of a local coupling distance of 400 nm. To do this,
we simulated data to match the raw the data. The model was able to reasonably replicate
the data (figure 4.11). We varied K to in the model to best replicate the raw data. This
resulted in K = 0.199 ± 0.044 µM. This lines up well with our previous estimate of K =
0.216 ± 0.055 from the single molecule data.
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To further test the model, we collected data with large ensembles with motility
experiments. This leads to strong local coupling, as the concentration of myosin was 100
µg/mL. In such conditions, myosin can activate the thin filament through strong binding,
even at low Ca++. This is achieved by reducing the ATP levels and thus prolonging the
strongly bound rigor state of myosin. Such conditions allow one strongly bound myosin
to push tropomyosin, allowing neighboring myosin to strongly bind as well. In the
absence of Ca++, we found that rigor myosin were able to activate the thin filament and
increase velocity as a function of ATP. We found that for low Ca++ conditions (pCa 9),
60 µM ATP was a critical point, where velocity decreased as ATP was increased beyond
60 µM. This agrees well with previous data (62). We tested the role of strong binding
activation by repeating these experiments with different Ca++ concentrations. We found
that 60 µM was a critical point for many other Ca++ concentrations. We used the model to
match the experimental data (figure 4.12). We determined values of ε to optimize the fit
of the data. The data were well fit by equations (1) and (2), and generated a value for K =
0.217 ± 0.034 µM.
The estimate of ε along with the fits are surprisingly similar to the fits generated
for the single molecule and small ensemble data. The model is able to explain thin
filament activation across many levels, and is able to tease apart the role of Ca++ and
myosin strong binding on thin filament activation.
R146G Mutation
In addition to examining thin filament activation with wild type regulatory
proteins, we examined the effect of a cardiomyopathy-inducing mutated troponin. This
particular mutation has proven to be a difficult to understand due to the lack of consensus
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of the mutation’s effect as well as the odd result that the mutation seems to not only
affect myosin’s on-rate but also other steps of the crossbridge cycle (we expect troponin
to affect myosin’s weak to strong transition, but not other steps such as ADP release or
ATP binding). To address this, we measured the velocity of regulated thin filaments in
the in vitro motility assay either in the presence or absence of the mutant.
The Effect of the R146G Mutation on pCa-Velocity
Our first test was to examine the mutant’s effect on the pCa-velocity relationship
(figure 4.13). Under high Ca++ concentrations, the filaments with the R146G mutation are
moving but are significantly slower than filaments with wild-type troponin. However,
under low Ca++ conditions, filaments with the mutation move significantly faster than
wild-type. Similar findings have been found with force measurements in muscle fibers
(69, 70, 114, 129). The reduced velocity under high Ca++ conditions and the relative
increase in velocity under low Ca++ conditions may explain the data’s poor fit to the Hill
equation. The wild type is well fit with the Hill equation (R2 = 0.97), however, the mutant
is poorly fit (R2 = 0.31). The results also show a leftward shift in the curve and a
subsequent increase in the pCa50, suggesting earlier activation with the mutation. This
result is in agreement with many (12, 34, 70, 114, 129), but not all (69), of the previous
studies examining this mutation’s effect on Ca++ sensitivity in force and ATPase
measurements.
The Effect of the R146 Mutation on duty cycle
To identify the mechanism of the R146G mutation, we measured the velocity of
thin filaments in a duty cycle motility assay. In this motility assay, the myosin
concentration is manipulated and the resulting velocities are fit to the duty cycle equation
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(see Methods: Regulated Thin Filament Velocity Analysis) (120). This assay gives an
estimate of the percentage of myosin heads bound to the regulated thin filament at any
given moment. The increase in the pCa50 suggest that the mutant would increase the duty
cycle, however, our results show a slight decrease in duty cycle in the presence of the
mutation, from 1.81% to 1.39% (figure 4.14). Our results also showed a reduced velocity,
even at maximum myosin concentration, from 4.63 ± 0.15 µm/s with the wild-type to
2.49 ± 0.11 µm/s with the mutant. To be sure that this didn’t affect our duty cycle result,
we normalized the duty cycle results; this however, did not change the outcome. A
possible explanation for the pCa-velocity and duty cycle results is that the R146 mutant
slows ADP release, leading to slower maximal velocities but higher velocity at low Ca++,
in addition to dramatically reducing myosin’s on-rate. If the on-rate is slowed
significantly more than the ADP release rate, the overall effect would be a reduction in
the duty cycle, as we observed.
The effect of the R146G Mutation on ADP release
To further explore the effect of the mutant on myosin’s kinetics, we measured
regulated thin filament velocity as a function of ATP concertation (figure 4.16). These
data were fit to a Michaelis-Menten relationship and the parameters are shown in Table
4.3. Again, the maximum velocity was reduced in the presence of mutation relative to the
wild type, decreasing from 4.54 ± 0.13 µm/s to 2.56 ± 0.06 µm/s. To examine ADP
release rate, the data was converted to time on (ton), which is the displacement generated
by 1 myosin head, assumed to be 10 nm (d=10 nm), divided by the velocity of the thin
filament (ton = d / V). The ton data can then be used to estimate ADP lifetime and rigor
lifetime, assuming that ton is made up entirely of ADP lifetime at saturating ATP and that
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ton = the time of the ADP lifetime plus the time of rigor where myosin is waiting for ATP
to induce actomyosin dissociation (ton = t-ADP + trigor). Our results show a reduction in the
ADP release rate in the presence of the mutation (figure 4.17, table 4.3), decreasing from
401.3 s-1 with the wild type to 248.4 s-1 with the mutant.
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CHAPTER 5
DISCUSSION
With our first set of experiments, we were able to examine thin filament
activation and tease apart the role of Ca++ and myosin strong binding. Our first set of
experiments give us a better understanding of thin filament activation under normal
conditions, and we hope to use this knowledge to examine perturbations, such as acute
changes in metabolites or chronic mutations in key muscle proteins. In our second set of
experiments, we examined a specific mutation in troponin that is associated with
cardiomyopathy.
Thin Filament Activation
According to the 3-state model (81), thin filament activation requires both Ca++
binding to Tn as well as myosin strong binding to the thin filament. However, the role
that each of these play in activation are unclear. Some have suggested that strong binding
doesn’t play a crucial role under physiological ATP levels (41). Others have suggested
that myosin’s weak to strong binding transition is Ca++ independent (16). To better
understand the significance of each mechanism, we directly observed single molecules,
small ensembles, and large ensembles of myosin bind to actin under a spectrum of Ca++
concentrations. This is the first time, to our knowledge, that force and motion of single
and small ensembles of myosin have been directly observed under such a wide range of
Ca++ concentrations. Such experiments give us a bottom-up view of thin filament
activation and can help us tease apart the role of Ca++ and strong myosin binding.
Single Molecule Binding
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Single myosin binding to a single thin filament was observed in the laser trap at
various Ca++ levels. As Ca++ is reduced, binding events became less frequent, declining
from 0.85/s at pCa 4 down to 0.02/s at pCa 9. This data agrees with models that suggest
Ca++ affects myosin’s weak to strong binding transition and disagrees with models that
suggest Ca++ alters other kinetic steps, such as phosphate release (16). Our data and
model do also do not support the notion that Ca++ has an allosteric effect on the thin
filament which controls myosin binding (16, 53, 117).
Even at saturating Ca++, the binding frequency was only 0.85/s, more than half the
binding frequency observed with an unregulated actin filament (2.2/s). Similar findings
have been obtained in a landing assay, where the ability of S1 myosin to land on a Ca++activated thin filament was reduced compared to an unregulated actin filament (29).
Mathematical models have included this, suggesting that there is still an energy barrier
that myosin must overcome, even at saturating Ca++ (126, 127). Solution experiments
have also shown that ATPase is inhibited at low S1 myosin concentrations in the
presence of regulatory proteins and saturating Ca++ (72).
Under the conditions of the laser trap, the thin filament is placed close to the top
of the 3 µm myosin-coated mogul. In this experiment, the height is crucial: filament
heights above 3.5 µm or below 3.0 will result in either no binding or unproductive
binding between either actin and myosin or actin and the surface of the mogul.
Differences in height across Ca++ concentrations could lead confounding results. To
ensure our single molecule binding was indeed Ca++ dependent and not due to
experimental error in height, an image of the mogul was captured during data collection
and analyzed after the experiment. Any recordings collected out of our range of 3.0 to 3.5
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µm was disregarded. We found that the height of the thin filament was not significantly
different from pCa 4 to pCa 9 (figure 4.2)
Myosin Ensembles
Our single molecule binding frequency data could be fit to a pCa curve. Though
the fit is good (figure 4.10), the Hill coefficient is low (1.4 ± 0.3)This does not agree well
with pCa-force curves, which can show Hill coefficients up to 6 (9). Our low Hill
coefficient confirms that some cooperativity exists even in the absence of multiple
myosin. Cooperativity can occur in four main ways: 1) coupling between the two Ca++
binding sites on fast skeletal TnC, 2) coupling between Ca++ binding sites down the thin
filament, 3) myosin strong binding inducing Ca++ binding to TnC, and 4) myosin strong
binding inducing movement of tropomyosin into an open state so other myosin can more
easily bind (44). The first two mechanisms may play a role, but can only produce Hill
coefficients up to 1.2 or 1.5, respectively (46). Though these mechanisms contribute, they
do not seem to be the main mechanism(s) of the cooperativity observed in thin filament
activation. Mechanism (4), where myosin strong binding induces other neighboring
myosins to strongly bind, could play a larger role than other mechanisms. Indeed, the
importance of strong myosin binding has been demonstrated with NEM myosin, which
strongly bind to actin but do not release. Experiments have shown that rigor or NEM
myosin are capable of activating a thin filament (49, 111). Experiments with fluorescent
probes in fibers (112) have compared the overlap region to the nonoverlap region and
showed that endogenous myosin binding leads to S1 binding in the overlap region, but
not in the nonoverlap region. Though many examples exist to demonstrate strong-binding
cooperativity, some question the physiological relevance of this mechanism (41). This
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concern is valid, as these previous experiments were done at very low ATP, much lower
than physiological levels. Recent work has shown that Tn and Tm dynamics are much
faster than myosin kinetics, suggesting that myosin strong binding would not play a large
role in activation (41).
By using a small ensemble of myosin in the laser trap at 100 µM ATP, we could
examine the role of myosin strong binding under near-physiological conditions. This
ATP concentration is up to 1,000x typical myosin strong binding experiments. Further,
with this ATP concentration, we would expect short but detectable (10 ms) binding
durations per each myosin. At high Ca++, the myosin ensembles produced a wide
distribution of forces. Interestingly, most of the events produces low force (1-2 pN),
though some binding events went as high as 11 pN. As Ca++ was reduced, these larger
forces disappeared. For example, the highest force produced at pCa 7 was 3 pN, and pCa
9 produced events that looked like single molecule events.
To further examine the role of Ca++ and strong binding myosin in activating the
thin filament, we performed motility experiments while manipulating Ca++ and ATP.
Previous work has shown that at high Ca++, motility velocities are well described by a
Michaelis-Menten relationship as ATP is increased. However, at low Ca++, velocity rises
up until ~60 µM ATP, and then slowly declines (62). We build off of this previous work
by examining the effect of a wide range of Ca++ levels, from pCa 9 to pCa 4. Our data
confirm that 60 µM is a critical ATP concentration.
Mathematical Model
To separate the effects of Ca++ and myosin strong binding, we compared our data
to a mathematical model. The model was able to replicate the experimental data well at
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all levels (single molecule, small ensemble, large ensemble). Impressively, the model
generated values for the Tn- Ca++ binding affinity that are extremely similar across all
three levels. In addition, the model was able to tease apart the role of Ca++ and myosin
strong binding. Using the model, we were able to extrapolate force generation as if each
myosin molecule acted independently (i.e., no myosin strong binding activation or
cooperativity. The resulting pCa-force curve had a low Hill coefficient (1.4 ± 0.3) and
low pCa50 value (5.96). Even if we
tried to shift the curve to line up
with pCa-force data collected in
fibers, the curve is still not steep
enough to match these data.
However, once myosin strong
binding activation is added into the
model, the model is able to
recapitulate a typical pCa-force

Figure 5.1. pCa-force relationship for single molecule data and
our model. We fit our single molecule binding data to a pCa
curve. This curve is shallow and shifted to the right compared
to pCa-force data from fibers. The model incorporates
cooperativity, and can therefore duplicate experimental data
with an appropriate Hill coefficient and pCa50.

curve. The model recapitulates data generated from single muscle fibers (85), with a Hill
efficient of 1.7 ± 0.2 and a pCa50 of 6.81 (figure 5.1). Therefore, myosin strong binding
activation is necessary to describe experimental data.
The model predicts myosin are locally coupled if they are within 400 nm of each
other. In the model, if two strongly bound myosin are within this range, then the thin
filament is activated between the two myosins. Further, if one myosin is strongly bound,
the probability of a neighboring myosin also binding is increased. This probability is
affected by how close the second myosin is: the closer the second myosin is to the first
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myosin, the higher the increase in probability of the second myosin binding. An
important note is that this length of
400 nm (ℓ) is not the same as the
cooperative unit length (µ), as ℓ
implies only partial activation. In
other words, an increase in the
attachment rate would be
miniscule 400 nm from the point
of first attachment because the
function drops off rapidly away
from the site of first attachment.
Assuming tropomyosin is a
flexible chain, we feel that ℓ better

Figure 5.2. Depiction of the mathematical model. Top: two
myosin activate the region between them (red). Regions with only
one myosin bound (white) lead to partial activation for a distance.
Middle: model of tropomyosin’s position, depending on myosin
strong binding. Bottom: probability (ka) of neighboring myosin
binding.

captures the effect of strongly bound myosin, and the model better encapsulates myosin
strong binding activation compared to models that use the cooperative unit. Further, the
cooperative unit length has been hard to determine, with ranges from 40 nm to 500 nm
(62, 74, 77, 80, 97, 103, 122). Meanwhile, ℓ has been determined to be 400 nm. Indeed,
previous experiments have led to this conclusion (127), and our current results support
this distance. In fact, for the model to fit our data, a coupling length of 400 ± 100 nm was
not only sufficient but necessary. Thus, our data confirm the model’s prediction of the
coupling length between myosin, regardless of the number of myosin present.
Based on the myosin concentration used and the geometry of the experimental
setup (in particular, the use of a 3 µm bead as a pedestal for myosin), we expect ~7
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myosin molecules could interact with the thin filament (27, 51). The mathematical model
we used suggests that 14-22 myosin were available. We attempted to reconcile this
difference by using TIRF to quantify the number of myosin in a given area, and compare
this value to the area on the 3 µm pedestal that would provide myosin the ability to bind
to thin filament. Unfortunately, there was much variability in this experiment. Regardless
of the exact number of myosin, the myosin molecules would have had to at least
communicate over a distance of 36 nm. This assumes that the 3 µm pedestal bead
provides a ~500 nm region where myosin can reach the thin filament. If 14 myosin were
evenly spaced out on this 500 nm region, they would be 36 nm apart, on average. If the
number of myosin was closer to 7, they would be 71 nm apart, on average. Thus,
cooperativity observed in our experiments is likely not due to cooperative binding of
myosin within a regulatory unit, but rather due to cooperative binding of myosin beyond
their own regulatory unit. This concept is confirmed by our data, as the local coupling
length in the model is 400 nm.
Limitations
The performed experiments do not go without limitations. Future experiments can
provide more detail into the molecular mechanisms of thin filament activation with
improvements on the current experiments. The first limitation is the use of 100 µM ATP.
We chose this concentration because it allows us to detect many binding events. Higher
concentrations could lead to events that occur so quickly that our system would not detect
it (>5 ms). On the other hand, we wanted to ensure that myosin was in the form of
ADP.Pi, and not ADP or rigor. We are confident, based on the ATP binding constant of
myosin, that we achieved our goal.
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The second limitation is the random configuration of myosin on the 3 µm mogul.
To better recapitulate muscle in vivo, future experiments could use reconstituted thick
filaments. Such filaments can be designed to not only duplicate the spacing of myosin in
vivo, but could also be manipulated to add extra myosin or take myosin away. A nice
feature would be the ability to count the myosin interacting with the actin filament. This
could be done possibly by dual color microscopy, where the actin and myosin are labeled
with different color fluorophores.
The third limitation is the shape of the 3 µm mogul. The curved surface of the 3
µm mogul leads to particular phenomena, such as different binding rates of the first and
second myosin during a small ensemble run. Future experiments could examine a flat
pedestal instead of round one. Maybe even more important is the ability to control the
thin filament in the Z-axis. Current microscopes provide feedback to maintain the height
of the experimental set up, but many do not have nm resolution.
R146G Mutation
Of the three subunits of troponin, the inhibitory region, TnI, is responsible for
binding to actin in the absence of Ca++ and subsequently keeping tropomyosin in the
blocked state. Upon Ca++ binding, TnI detaches from actin and binds to TnC, allowing
tropomyosin to move freely over the actin surface. A key part of TnI’s function is the
inhibitory region, which spans residues 96-116 on skeletal TnI and 126-146 on cardiac
TnI, and is responsible for binding to actin in the absence of Ca++. This places our
mutation of interest, R146G, just within this key inhibitory region.
The data for this mutant are equivocal for many measurements. Some have found
that force is reduced in the presence of the mutant at maximal Ca++ (70, 129), but others
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have not seen this (114, 132). Similarly, some have found that ATPase is reduced (70,
114), but others have not seen this (34, 129), and some have seen that velocity is reduced
in motility (12), but not in fibers (60). The results make it difficult to say clearly if this
mutant has an effect at all on peak force, ATPase, or velocity. However, most work
agrees that there is a shift in the pCa50 across ATPase, force, and velocity measures (12,
60, 70, 114, 129, 132).
We have collected data in agreement with previous findings. Under maximal Ca++
conditions, we see a ~46% reduction in velocity. We also see a leftward shift in the pCavelocity relationship. To try to tease apart the mechanism behind this, we examined the
ADP release rate and the duty ratio. We found that the duty ratio decreased ~22%, from
1.8 to 1.4%. In separate experiments, we found that the ADP release rate was reduced by
~38%. What follows is set of possible explanation for these phenomena.
The observed decrease in velocity, even in the presence of maximal Ca++, is in
agreement with previous findings. The reduced velocity can happen if myosin’s kinetics
are altered. One of myosin’s kinetic steps that may be slowed is the weak to strong
transition. This is the step that the regulatory proteins control, and the R146G mutant may
impede myosin’s weak to strong transition more than the wild-type Tn. Previous data (29,
126, 127) and our data presented here suggest that the weak to strong transition rate is
reduced in the presence of regulatory proteins, even at maximal Ca++. The mutant may
exacerbate this reduction. The structural mechanism could be that the mutant TnI, rather
than binding to TnC at maximal Ca++, stays attached to actin, keeping tropomyosin in the
blocked state. Some of the TnI molecules may come off of actin, but a high enough
percentage may stay bound to actin, preventing complete thin filament activation. To test
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whether the myosin’s weak to strong transition was limited, we performed duty cycle
experiments. In these experiments, velocity is measured as a function of myosin
concentration. The data can be fit to the duty cycle equation to determine the percentage
of myosin molecules bound at any given time. The presence of the mutant induced a
reduction in the duty cycle from 1.8 to 1.4%. These duty cycles are relatively low
compared to previous measures, but a relative comparison would imply that myosin
spend less time on actin in the presence of the mutant. This could be due to a reduction in
the weak to strong transition rate.
Alternatively, the reduction in velocity could be due to a reduced ADP release
rate. Our duty cycle experiments would suggest that this step is not the culprit, as a
reduced ADP release rate would prolong myosin’s time attached to actin and thus
increase the duty ratio. This would be in disagreement with our findings. To be sure, we
completed experiments to calculate the ADP release rate by measuring velocity as a
funciton of ATP. We assume that the mutant does not affect the ATP binding constant of
rigor myosin. When we fit these velocity-ATP data, we found that the ADP release rate
was indeed reduced in the presence of the mutant. Based on the duty cycle experiments,
the reduction in ADP release rate was not expected but is still possible: both the weak to
strong transition rate and the ADP release rate may be slowed, but the former is slowed to
a greater extent than the latter. This would lead to reduced velocity as well as a reduced
duty cycle.
How the weak to strong transition could be altered by a Tn mutant may be easy to
explain, how the Tn mutant would alter ADP release is unclear. The Tn mutant may
interact with myosin and can alter its kinetics. Though this is possible based on the
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proximity of myosin to the regulatory proteins, this Tn-myosin interaction seems
unlikely, considering TnI can only reach two of the seven actin monomers in a regulatory
unit, and would thus only be able to affect myosin if the myosin was bound to those actin
monomers. Recent investigations have made progress in examining the interactions of
myosin-thin filament residues using cryo-EM (124, 125), but currently lack the ability to
characterize the loose C-terminal of TnI.
To further complicate matters, we found, in agreement with previous work, that
the mutant induces a leftward shift in the pCa-velocity relationship. This would seem to
complicate the story, as a leftward shift isn’t expected when myosin’s on-rate is slowed.
However, a reduced ADP release rate may contribute to strong binding activation. The
longer myosin stays bound to actin, the higher the probability of a neighboring myosin
binding as well.
The pCa-velocity relationship in the presence of the mutant is not fit well
(R=.307). Indeed, the difference in velocity between low Ca++ and high Ca++ is only 1
µm/s. It seems that the mutant isn’t very sensitive to Ca++ at all. Others have shown that
peak velocity or ATPase is reduced at maximal Ca++ compared to wild type, yet the thin
filaments with the mutant are not able to completely inhibit ATPase activity. Assuming a
three-state model of regulation, the vast majority (~99%) of myosin binding sites on actin
should be blocked. However, the R146G mutation may limit TnI’s ability to bind to actin,
allowing tropomyosin to move freely around the closed state and increasing myosin’s
probability of binding to actin. Conversely, the mutated TnI may not bind to TnC as well
as the wild-type during maximal Ca++ activation. Thus, thin filaments in the presence of
the R146G mutation fluctuate between blocked, closed and open, regardless of Ca++, and
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the distribution of these three states is not strongly dependent on Ca++ compared to wildtype proteins. Others have confirmed this idea, suggesting that the R146G mutant
stabilizes the closed position (61). Determining the precise distribution of open, closed,
and blocked from our data is not possible, but future work examining single molecule and
small ensembles in the laser trap, along with mathematical modeling, could provide
insight.
Future work could examine how this mutant (and other mutants) affect single
myosin molecule binding as well as other kinetic steps. This can be done using the laser
trap assay. Our current findings suggest that both the weak to strong transition as well as
ADP release are slowed in the presence of R146G. A single molecule laser trap assay
would be able to directly observe this behavior. It would then be possible to examine how
this single molecule behavior affects a small ensemble of myosin in producing force and
motion. Further, these measures can be examined over a range of Ca++ concentrations,
which would provide insight into the leftward shift in the pCa-velocity relationship.
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TABLES AND FIGURES

Table 4.1: Events per Second for Single
Molecule Binding Events
pCa
Events per Second
4

0.85

5

1.11

6

0.45

7

0.23

9*

0.01

*pCa 9 was published by Kad 2005 (62)
Table 4.2: Significant Differences of Ensemble Forces
between Ca++ Concentration
Significant
Comparison
Difference
pCa 5

vs.

pCa 5
pCa 5

vs.
vs.

pCa 6
pCa 6
pCa 6.5

vs.
vs.
vs.

pCa 6
pCa
6.5
pCa 7
pCa
6.5
pCa 7
pCa 7

No
Yes
Yes
Yes
Yes
Yes

Table 4.3: Fit parameters for R146G data
Measure
WT
Vmax (µm/s)
4.54 ± 0.13
Km (µM)
264 ± 33
ADP Lifetime (s)
0.0024
ADP Release Rate (s-1)
410.29

79

R146G
2.56 ± 0.06*
132 ± 17
0.0040*
248.37*

Figure 4.1. Sample traces of single molecule binding events at pCa 4 (left) and pCa 7 (right). Single
molecule binding events became less frequent as Ca++ was reduced.

Figure 4.2. Height of a regulated thin filament in the single molecule laser trap assay. The height of the RTF
was not significantly different from pCa 4 to pCa 9.
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Figure 4.3. Step size in single molecule experiments. The step size was not significantly different across
pCa levels.

Figure 4.4. Attachment time during single molecule experiments. The attachment time was not significantly
different across pCa levels.
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Figure 4.5. Force Histograms for each pCa. Events were most frequent and most likely to produce
high forces at pCa 5. Event frequency and peak force declined as Ca++ was reduced. Events were
extremely rare at pCa 9, as shown by the inset.
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Figure 4.6. Histogram of Event Duration for each pCa. At pCa 5, events lasted for hundreds of
milliseconds, but duration declined as Ca++ was reduced. Despite the high myosin concentration,
events at pCa 9 typically lasted less than 15 ms.
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Figure 4.7. Relationship between Force and Duration at pCa5. As the myosin ensemble generated force, the
event duration was prolonged.
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Figure 4.8. Time between events at each pCa. At pCa 5, events occurred in repid succession. However, as
Ca++ was reduced, events became less frequent. At pCa 9, the time between events was many seconds.
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Figure 4.9. Velocity of regulated thin filaments as a function of Ca++ and ATP in an in vitro motility assay. At
pCa 4, velocity follows a typical Michaelis Menten relationship. However, at pCa 9, there exists an ideal ATP
level to generate maximum velocity. The velocity depends not only on actomyosin binding sites availability,
which is partially dictated by Ca++, and myosin on-time, which is dictated by ATP binding.

Figure 4.10. Comparing our single molecule data to the mathematical model. The single molecule binding
rate directly measured was well fit by the mathematical model.
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Figure 4.11. Comparing our small ensemble data to the model. The force and on-time were converted to a
relative frequency (gray bars) and are well fit by the mathematical model (red line).

Figure 4.12. Comparing our large ensemble data to the model. The thin filament speed is well fit by the
model, regardless of ATP and Ca++.
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pCa vs. Velocity: WT and R146G
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Figure 4.13. pCa-Velocity relationship generated in an in vitro motility assay. Wild-type (black) produced a
typical sigmoidal curve, while the mutant (white) was poorly fit to the Hill equation due to low velocity at
maximum Ca++ and elevated velocity at low Ca++.
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Figure 4.14. Velocity as a function of available myosin heads in an in vitro motility assay. Also known as a
duty cycle assay, the myosin concentration was manipulated and number of heads available was estimated
using the data in Harris and Warshaw 1993 (51). The duty cycle was slightly lower with the mutant (1.39%,
white) while the wild-type (black) was 1.81%.
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Figure 4.15. Same data as Figure 4.9, but shown here normalized to each Tn variant's peak velocity. This
better shows how similar the duty cycle is between each condition.
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[ATP] vs. Velocity: WT and R146G
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Figure 4.16. Velocity of each Tn variant as a function of ATP. By measuring velocity as a function of ATP,
we can calculate the ADP release rate (table 4.3)
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Figure 4.17. Using the same data in figure 4.11, we can calculate time on by measuring velocity and by
assuming that myosin displaces actin 10 nm with each powerstroke.
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